



# Indispensable Role of CX<sub>3</sub>CR1<sup>+</sup> Dendritic Cells in Regulation of Virus-Induced Neuroinflammation Through Rapid Development of Antiviral Immunity in Peripheral Lymphoid Tissues

Jin Young Choi<sup>1†</sup>, Jin Hyoung Kim<sup>1†</sup>, Ferdous Mohd Altaf Hossain<sup>1,2</sup>, Erdenebelig Uyangaa<sup>1</sup>, Seong Ok Park<sup>1</sup>, Bumseok Kim<sup>1</sup>, Koanhoi Kim<sup>3</sup> and Seong Kug Eo<sup>1\*</sup>

## OPEN ACCESS

### Edited by:

Simon Yona,  
University College London,  
United Kingdom

### Reviewed by:

E. Ashley Moseman,  
Duke University, United States  
Jian Zheng,  
The University of Iowa, United States

### \*Correspondence:

Seong Kug Eo  
vetvirus@chonbuk.ac.kr

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Antigen Presenting Cell Biology,  
a section of the journal  
Frontiers in Immunology

**Received:** 15 November 2018

**Accepted:** 11 June 2019

**Published:** 27 June 2019

### Citation:

Choi JY, Kim JH, Hossain FMA, Uyangaa E, Park SO, Kim B, Kim K and Eo SK (2019) Indispensable Role of CX<sub>3</sub>CR1<sup>+</sup> Dendritic Cells in Regulation of Virus-Induced Neuroinflammation Through Rapid Development of Antiviral Immunity in Peripheral Lymphoid Tissues. *Front. Immunol.* 10:1467. doi: 10.3389/fimmu.2019.01467

<sup>1</sup> Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, South Korea, <sup>2</sup> Faculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, Bangladesh, <sup>3</sup> Department of Pharmacology, School of Medicine, Pusan National University, Yangsan-si, South Korea

A coordinated host immune response mediated via chemokine network plays a crucial role in boosting defense mechanisms against pathogenic infections. The speed of Ag presentation and delivery by CD11c<sup>+</sup> dendritic cells (DCs) to cognate T cells in lymphoid tissues may decide the pathological severity of the infection. Here, we investigated the role of CX<sub>3</sub>CR1 in the neuroinflammation induced by infection with Japanese encephalitis virus (JEV), a neurotrophic virus. Interestingly, CX<sub>3</sub>CR1 deficiency strongly enhanced susceptibility to JEV only after peripheral inoculation via footpad. By contrast, both CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice showed comparable susceptibility to JEV following inoculation via intranasal and intraperitoneal routes. CX<sub>3</sub>CR1<sup>-/-</sup> mice exhibited lethal neuroinflammation after JEV inoculation via footpad route, showing high mortality, morbidity, pro-inflammatory cytokine expression, and uncontrolled CNS-infiltration of peripheral leukocytes including Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes. Furthermore, the absence of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs appeared to enhance susceptibility of CX<sub>3</sub>CR1<sup>-/-</sup> mice to JE after peripheral JEV inoculation. CX<sub>3</sub>CR1 ablation impaired the migration of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs from JEV-inoculated sites to draining lymph nodes (dLNs), resulting in decreased NK cell activation and JEV-specific CD4<sup>+</sup>/CD8<sup>+</sup> T-cell responses. However, CX<sub>3</sub>CR1-competent mice showed rapid temporal expression of viral Ags in dLNs. Subsequently, JEV was rapidly cleared, with concomitant generation of antiviral NK cell activation and T-cell responses mediated by rapid migration of JEV Ag<sup>+</sup>CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs. Using biallelic functional CX<sub>3</sub>CR1 expression system, the functional expression of CX<sub>3</sub>CR1 on CD11c<sup>hi</sup> DCs appeared to be essentially required for inducing rapid and effective responses of NK cell activation and Ag-specific CD4<sup>+</sup> T cells in dLNs. Strikingly, adoptive transfer of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs was found to completely restore the resistance of CX<sub>3</sub>CR1<sup>-/-</sup> recipients to

JEV, as corroborated by the rapid delivery of JEV Ags in dLNs and attenuation of neuroinflammation in the CNS. Collectively, these results indicate that CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs play an important role in generating rapid and effective responses of antiviral NK cell activation and Ag-specific T cells after peripheral inoculation with the virus, thereby resulting in conferring resistance to viral infection by reducing the peripheral viral burden.

**Keywords:** CX<sub>3</sub>CR chemokine receptor, Japanese encephalitis, dendritic cells, neuroinflammation, antiviral immunity

## INTRODUCTION

Japanese encephalitis (JE) is a leading cause of viral encephalitis characterized by extensive neuroinflammation in the central nervous system (CNS) and disruption of the blood-brain barrier (BBB) following infection with JE virus (JEV). The zoonotic, mosquito-borne JEV is a single-stranded, positive-sense RNA virus and is endemic to the Asia-Pacific region, including China, India, and northern Australia (1). Competent vectors for JEV have been recently identified in Germany (2). Notably, porcine transmission of JEV in the absence of mosquitos increases the risk of viral spread and persistence in regions with moderate climate (3). Thus, JEV is becoming a worldwide public health concern. In humans, the clinical presentation of JEV infection ranges from mild febrile illness to severe meningoencephalitis, with nearly 70,000 fatal cases reported annually (4). While most JEV infection in the endemic regions manifests as a mild febrile and subclinical disease that leads to protective immunity, approximately 25–30% of JE cases, involving mostly infants, are lethal and 50% of cases result in permanent neuropsychiatric sequelae (1). Thus, JEV is considered more lethal than the West Nile virus (WNV) infection, which is associated with a fatality rate of 3–5% (1,100 deaths/29,000 symptomatic infections) (5). Vaccination programs are available in endemic regions at risk (6).

Considerable progress in understanding the kinetics and mechanisms of JEV dissemination and JE pathogenesis has been made using murine models (7–9). Following peripheral inoculation of the virus via mosquito bites, JEV initially replicates in peripheral dendritic cells (DCs) and macrophages, eventually invading the CNS through the blood-brain barrier (BBB) (10, 11). JE is considered a neurological and immunopathological disease characterized by uncontrolled hyperimmune response triggered by viral invasion of the CNS (12, 13). While JEV-specific T cells and virus-neutralizing IgM and IgG clear the virus from both peripheral lymphoid tissues and the CNS (14), innate immune response appears to play a critical role in the early control of JEV infection due to delayed adaptive immunity (8, 9, 15). Therefore, type I IFN (IFN-I, typically IFN- $\alpha/\beta$ ) innate immune response is essential for control of JEV. Recent data also indicated that type II IFN (IFN-II, IFN- $\gamma$  being the only member) produced from NK and CD4<sup>+</sup> Th1 cells has a positive effect on disease outcome after JEV infection (8, 9).

**Abbreviations:** APCs, antigen-presenting cells; BBB, blood-brain barrier; CNS, central nervous system; DCs, dendritic cells; dLNs, draining lymph nodes; dpi, days post-infection; IFN-I, type I interferon; IFN-II, type II interferon; JEV, Japanese encephalitis virus; WNV, West Nile virus.

Coordination between host's innate and adaptive immune response is crucial in regulating infectious diseases caused by various pathogens, including JEV. In particular, the speed at which the host innate and adaptive immune cells respond to infection is critical to the clinical outcome (16). CD11c<sup>+</sup> dendritic cells (DCs) are professional antigen-presenting cells (APCs) and key instigators of protective immunity (17). Detailed information on the molecular mechanisms underlying the role of CD11c<sup>+</sup> DCs to initiate protective immunity has solidified their roles in determining the outcomes of infectious diseases (17). The speed that CD11c<sup>+</sup> DCs deliver and present Ags to cognate T cells in lymph nodes (LNs) through their migration from inflammatory sites may decide the severity of infectious disease. Therefore, understanding the sensitivity of CD11c<sup>+</sup> DCs in detecting peripheral pathogen invasion and relay of Ags to adaptive immune cells in draining LNs (dLNs) is needed to develop strategies for effective induction of protective immunity.

The speed of host innate immune response including CD11c<sup>+</sup> DCs to peripheral pathogen infection is controlled by inflammatory mediators such as chemokines (18–20). Chemokine-driven migration of host innate and adaptive immune cells at the periphery and within lymphoid tissues is a key step in the generation of effective protective immunity. Among the members of the chemokine super-family, CX<sub>3</sub>CL1 (fractalkine) belonging to CX<sub>3</sub>C subfamily is unique in that the first two conserved cysteine residues in the chemokine are separated by three non-conserved amino acids (21). CX<sub>3</sub>CL1 is known to exist in two distinct forms: a membrane-anchored form and a soluble form. The soluble CX<sub>3</sub>CL1 acts as a chemoattractant whereas the membrane-anchored CX<sub>3</sub>CL1 functions as an adhesion molecule. CX<sub>3</sub>CL1 is expressed in endothelial cells (22), epithelial cells (22, 23), DCs (24, 25), and neurons (26) upon stimulation by pro-inflammatory cytokines such as IL-1 and TNF- $\alpha$  (27, 28). CX<sub>3</sub>CR1, a CX<sub>3</sub>CL1 receptor, potentially mediates both leukocyte migration and firm adhesion with two distinct expression patterns of CX<sub>3</sub>CL1 (29). CX<sub>3</sub>CR1 is expressed on leukocytes, including monocytes, T-cell subsets, NK cells (30, 31), microglia (32), neurons (33), astrocytes (34), and platelets (35). CX<sub>3</sub>CR1 is also expressed on most tissue macrophages and DCs. It is unlikely to be involved in their ontogeny, homeostatic migration, or colonization of tissues with resident macrophages (36, 37) except kidney DCs (38) and intestinal macrophages (39, 40). CX<sub>3</sub>CR1/CX<sub>3</sub>CL1 axis is involved in the pathophysiology of inflammatory conditions such as cardiovascular disease (41, 42), glomerulonephritis (38), and rheumatoid arthritis (43). Neutralization of CX<sub>3</sub>CL1 improves

cardiac function after myocardial infarction (41) and inhibition of CX<sub>3</sub>CR1 reduces atherosclerosis (44). Conversely, studies investigating the protective role of CX<sub>3</sub>CR1 showed an increased risk of liver fibrosis with the loss of CX<sub>3</sub>CR1 in a model of hepatic fibrosis (45). CX<sub>3</sub>CR1 is also required to develop resistance to pulmonary infection by vaccinia virus (46). These findings highlight the complexity of the CX<sub>3</sub>CR1/CX<sub>3</sub>CL1 axis in inflammatory diseases.

However, the role of CX<sub>3</sub>CR1 in the pathogenesis of virus-induced neuroinflammation such as JE has yet to be reported. Therefore, the objective of the present study was to elucidate the role of CX<sub>3</sub>CR1 in neuroinflammation induced by JEV, a neurotrophic virus. In the current study, CX<sub>3</sub>CR1-ablated mice showed increased susceptibility to JE only after peripheral inoculation of JEV infection via footpad, but not intranasally or intraperitoneally. CX<sub>3</sub>CR1 played an important role in the rapid delivery of JEV Ags in dLNs from the peripheral site of infection at an early stage after peripheral JEV inoculation. It also played an important role in viral clearance at the peripheral lymphoid tissues and the CNS by generating effective NK cell and JEV-specific T-cell responses. Furthermore, the delayed migration of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs from peripheral site to dLNs appeared to impair NK cell activation and JEV-specific T-cell response in CX<sub>3</sub>CR1-ablated mice. Ultimately, the adoptive transfer of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs to CX<sub>3</sub>CR1-ablated mice fully restored the protection against peripheral inoculation of JEV infection. Our results indicate that CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs are essential to host protection against JE after viral inoculation at the peripheral sites.

## MATERIALS AND METHODS

### Ethics Statement

All animal experiments described in the present study were conducted at Chonbuk National University according to the guidelines set by the Institutional Animal Care and Use Committee (IACUC) of Chonbuk National University, and were pre-approved by the Ethics Committee for Animal Experiments of Chonbuk National University (approval number: 2013-0028). The animal research protocol used in this study followed the guidelines set up by the nationally recognized Korea Association for Laboratory Animal Sciences (KALAS). All experimental protocols requiring biosafety were approved by the Institutional Biosafety Committee (IBC) of Chonbuk National University.

### Animals, Cells, and Viruses

Wild-type C57BL/6 (H-2<sup>b</sup>) control mice (5–6 weeks old, both female and male) were purchased from SAMTAKO (Osan, Korea), and CX<sub>3</sub>CR1-deficient (CX<sub>3</sub>CR1<sup>-/-</sup>, H-2<sup>b</sup>) mice were obtained from Taconic Biosciences (Rensselaer, NY, USA). The CX<sub>3</sub>CR1<sup>gfp/gfp</sup> (H-2<sup>b</sup>) mice originally obtained from Jackson laboratory (Bar Harbor, ME, USA) were generously provided by Dr. Doo Hyun Jung (Seoul National University, Seoul, Korea) and crossed with C57BL/6 mice to generate CX<sub>3</sub>CR1<sup>+/gfp</sup> heterozygous mice. The JEV Beijing-1 strain was propagated in a mosquito cell line C6/36 using DMEM supplemented with 2% FBS, penicillin (100 U/ml), and streptomycin (100 U/ml)

as described previously (47). The recombinant vaccinia virus expressing chicken ovalbumin (OVA) was obtained from Dr. Jonathan W. Yewdell (National Institutes of Health, Bethesda, MD, USA) and propagated in CV-1 (American Type Culture Collection, Manassas, VA, USA, CCL70) cell line (48). Virus stocks were titrated using conventional plaque or focus-forming assays and stored in aliquots at -80°C until use.

### Mouse Model of JE

CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice were infected with JEV [5.0 × 10<sup>7</sup> plaque-forming units (PFU)] via footpad [100 μl, (50 μl/each footpad)], intranasal (20 μl), and intraperitoneal routes (200 μl). Infected mice were monitored daily for mortality, morbidity (weight loss), and neurological disorders (paralysis of front and/or rear limbs, not moving but responsive). Mice were also scored daily for encephalitis signs and symptoms as described previously (49). The encephalitis score represented a progressive range of behaviors: (1) hunched, ruffled fur, (2) altered gait, slow movement, (3) immobile but responsive, (4) moribund and no response, and (5) death.

### Antibodies and Reagents

The following mAbs were obtained from eBioscience (San Diego, CA, USA) or BioLegend (San Diego, CA, USA) for FACS analysis and other experiments: FITC-labeled anti-CD4 (RMA4-5), CD45 (30-F11), CD11b (M1/70), CD3 (145-2C11), and CX<sub>3</sub>CR1 (SA011F11); PE-labeled anti-granzyme B (16G6), CD40L (MR1), CD8 (53-6.7), F4/80 (BM8), IFN-γ (XMG1.2), and CD11c (M1/70); PerCP/Cy5.5-labeled anti-mouse Ly-6C antibody (HK1.4) and IFN-γ (XMG1.2); PE-Cy7-labeled anti-NK1.1 (PK136); APC-labeled anti-Ly6-G (1A8), TNF-α (MP6-XT22), and CD49b-integrin alpha 2 (DX5); and biotin-labeled anti-IL-6 (MP5-32C11) and TNF-α (MP6-XT22). PE-labeled anti-mouse Tmem119 (106-6) was obtained from Abcam (Cambridge, MA, USA). The mAbs against non-structural protein 1 (NS1) and envelope glycoprotein protein (E) of JEV were also obtained from Abcam. The JEV epitope peptide of CD4<sup>+</sup> T cells [NS3<sub>563-574</sub> (WCFDGPRTNAIL)] or CD8<sup>+</sup> T cells [NS4B<sub>215-223</sub> (9SAVWNSTTA)] was chemically synthesized at Pepton (Daejeon, Korea). Phorbol-12-Myristate-13-Acetate (PMA) and ionomycin were purchased from Sigma-Aldrich (St. Louis, MO, USA).

### Quantitative Real-Time RT-PCR for Determination of Viral Burden and Cytokine Expression

Viral burden and cytokine/chemokine expression in inflammatory and lymphoid tissues were determined via SYBR Green-based real-time qRT-PCR. Mice were infected with JEV (5.0 × 10<sup>7</sup> PFU) via footpad inoculation and various tissues including popliteal LNs, spleen, and brain were harvested at different time points post-infection (pi). Total RNAs were extracted from the collected tissues using easy-BLUE (iNtRON, Inc., Daejeon, Korea) and subjected to real-time qRT-PCR using a CFX96 Real-Time PCR Detection system (Bio-Rad Laboratories, Hercules, CA, USA). Following reverse transcription of total RNA with High-Capacity cDNA Reverse Transcription Kits

(Applied Biosystems, Foster, CA, USA), the reaction mixture (20  $\mu$ l total) contained 2  $\mu$ l of template cDNA, 10  $\mu$ l of 2 $\times$  SYBR Premix Ex Taq, and 200 nM primers (**Supplementary Table 1**). These reactions were denatured at 95°C for 30 s and then subjected to 45 cycles of 95°C for 5 s and 60°C for 20 s. After completion of the reaction cycle, the temperature was increased from 65°C to 95°C at the rate of 0.2°C/15 s, and fluorescence was measured every 5 s to construct a melting curve. A control sample lacking template DNA was run with each assay. All measurements were performed at least in duplicate to ensure reproducibility. The authenticity of the amplified product was determined by melting curve analysis. All data were analyzed using Bio-Rad CFX Manager, version 2.1 analysis software (Bio-Rad Laboratories). The expression of cytokines and chemokines was normalized to the levels of housekeeping gene  $\beta$ -actin. Viral burden was expressed by the copy number of viral RNA per microgram of total RNA after calculating the absolute copy number of viral RNA in comparison with the standard cDNA template of viral RNA.

## Histopathological Examinations, Immunohistochemistry, and Confocal Microscopy

Histopathological examination was performed using brains derived from CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice infected with JEV. Brains were embedded in paraffin at 5 dpi, and 10- $\mu$ m sections were prepared and stained with H&E. Following deparaffinization, brain sections were also used for the detection of CD11b<sup>+</sup> myeloid cells by staining with anti-CD11b mAb. After antigen retrieval, endogenous peroxidases were quenched by incubating the slides in 3% H<sub>2</sub>O<sub>2</sub> for 15 min. The sections were then washed with PBS for 10 min. Endogenous avidin and biotin was blocked using a SuperBlock<sup>TM</sup> blocking buffer according to manufacturer instructions (Thermo Fisher Sci). The sections were then washed with PBS for 4 min. Primary antibodies (1:100 biotinylated anti-mouse CD11b, eBioscience) were applied for overnight at 4°C in a humidified chamber. After rinsing the slides in PBS, they were incubated in secondary antibody (1:500 HRP-conjugated streptavidin, eBioscience) for 30 min at room temperature. After washing with PBS for 5 min, color development was achieved by applying diaminobenzidine tetrahydrochloride (DAB) solution (Vector Laboratories) for 0.5–1 min. After washing in distilled water, the sections were counterstained with VECTOR methyl Green (Vector Laboratories), and cover-slipped using a mounting medium (Fisher Scientific). Sections were analyzed using a Nikon Eclipse E600 microscope (Nikon, Tokyo, Japan). For confocal microscopy staining, popliteal LNs and brain were collected at 2 and 5 dpi, respectively, and frozen in optimum cutting temperature (OCT) compound. Sections of 6–7  $\mu$ m in thickness were cut, air-dried, and fixed with 1:1 mixture of acetone and methanol for 15 min at –20°C. After washing with PBS three times, non-specific binding was blocked with 10% normal goat serum and cells were permeabilized with 0.1% Triton X-100. Staining was performed by incubating sections overnight in moist chambers at 4°C with FITC-conjugated anti-mouse

CX<sub>3</sub>CR1, APC-conjugated anti-mouse CD11c, and anti-JEV NS1 and E. Primary antibodies were detected with secondary PE-conjugated goat anti-mouse IgG (SouthernBiotech, Birmingham, AL, USA). Nuclei were counterstained with DAPI (4',6'-diamidino-2-phenylindole; Sigma-Aldrich). Fluorescence was observed using a confocal laser scanning microscope (Carl Zeiss, Jena, Germany).

## Cytokine ELISA

Sandwich ELISA was used to determine the levels of IL-6 and TNF- $\alpha$  cytokines in sera. ELISA plates were coated with IL-6 (MP5-20F3) and TNF- $\alpha$  (1F3F3D4) antibodies (eBioscience), and incubated at 4°C overnight. After plates were washed three times with PBS containing 0.05% Tween 20 (PBST), they were blocked with 3% non-fat-dried milk at 37°C for 2 h. Sera and standards for recombinant cytokine proteins (PeproTech, Rehovot, Israel) were added to these plates and incubated at 37°C for 2 h. Plates were washed again with PBST, and then biotinylated IL-6 (MP5-32C11) and TNF- $\alpha$  (polyclonal antibody) antibodies were added. The mixture was incubated overnight at 4°C followed by washing with PBST and subsequent incubation with peroxidase-conjugated streptavidin (eBioscience) at 37°C for 1 h. Color was then developed by adding a substrate (ABTS) solution. Cytokine concentrations were determined using an automated ELISA reader and SoftMax Pro4.3 by comparison with two concentrations of standard cytokine proteins.

## Analysis of Infiltrated Leukocytes in the CNS and Peripheral Lymph Nodes

Mice infected with JEV were perfused with 30 ml of HBSS at 2, 3, and 4 dpi via cardiac puncture of the left ventricle. Brains were then harvested and homogenized by gently pressing them through a 100-mesh tissue sieve, followed by digestion with 25 mg/ml of collagenase type IV (Worthington Biochem, Freehold, NJ, USA), 10 mg/ml DNase I (Amresco, Solon, OH, USA), and incubation with RPMI medium for 1 h at 37°C with shaking. Cells were separated by centrifugation at 800 $\times$ g for 30 min (Axis-Shield, Oslo, Norway) using Opti-prep density gradient (18/10/5%), and the cells were collected from 18 to 10% interface and washed twice with PBS. Leukocytes derived from popliteal LNs and spleen were prepared by gently pressing lymphoid tissues through 100-mesh tissue dishes. The cells were then counted and stained for CD45, CD11b, CD11c, Ly-6C, CX<sub>3</sub>CR1, and Ly-6G with directly conjugated antibodies for 30 min at 4°C. Finally, cells were fixed with 1% formaldehyde. Data collection and analysis were performed using a FACS Calibur flow cytometer (Becton Dickson Medical Systems, Sharon, MA, USA) with FlowJo software (Tree Star, San Carlos, CA, USA).

## Analysis and Activation of NK Cells

The activity of NK cells was assessed by their capacity to produce IFN- $\gamma$  and granzyme B (GrB) following brief stimulation with PMA and ionomycin (Sigma-Aldrich). Cells were obtained from popliteal LNs of CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice at 2 dpi and stimulated with PMA and ionomycin in the presence of monensin (2  $\mu$ M) to induce the expression of IFN- $\gamma$  (PMA 50 ng/ml plus ionomycin 750 ng/ml for 2 h) or granzyme B (PMA



50 ng/ml plus ionomycin 750 ng/ml for 4 h). The stimulated cells were washed twice with PBS containing monensin and surface-stained with CD3, NK1.1, and DX5 antibodies for 30 min at 4°C. After fixation, cells were washed twice with 1× Permeabilization Buffer (eBioscience) and subjected to intracellular IFN-γ and GrB staining in the buffer for 30 min at room temperature. Stained cells were washed twice with 1× Permeabilization Buffer (eBioscience) and FACS buffer. Analysis was then performed using a FACSCalibur flow cytometer (Becton Dickson Medical Systems) with FlowJo software (Tree Star).

## JEV-Specific Humoral and T-Cell Responses

Humoral responses against JEV were evaluated by JEV-specific IgM and IgG levels in sera using JEV E glycoprotein antigen (Abcam, Cambridge, UK). JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses were determined by intracellular CD154 (also called CD40L), IFN-γ, and TNF-α staining in response to stimulation with JEV epitope peptides. Surviving mice infected with 5.0 × 10<sup>7</sup> PFU JEV were sacrificed on day 7 pi and leukocytes were prepared from popliteal LNs. These leukocytes were cultured in 96-well-culture plates (5 × 10<sup>5</sup> cells/well) in the presence of synthetic peptide epitopes (NS1<sub>132–145</sub> and NS4B<sub>215–225</sub>) for 12 h and 6 h to observe CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, respectively. Monensin at concentration of 2 μM was added to antigen-stimulated cells 6 h before harvest. Cells were washed twice with FACS buffer containing monensin, surface-stained with FITC-anti-CD4 or CD8 antibodies for 30 min at 4°C, and then washed twice with PBS containing monensin. After fixation, cells were washed twice with 1× Permeabilization Buffer (eBioscience) and stained with PepCP-Cy5.5 anti-IFN-γ or APC-anti-TNF-α in the permeabilization buffer for 30 min at room temperature. Intracellular CD154 was detected by addition of CD154 mAb to culture media during peptide stimulation, as described previously (8, 9). Finally, cells were washed twice with PBS and fixed using the fixation buffer. Sample analysis was performed using a FACS Calibur flow cytometer (Becton Dickson Medical Systems) with FlowJo software (Tree Star).

## Purification and Adoptive Transfer of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs

CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs were purified from spleens of CX<sub>3</sub>CR1<sup>+/gfp</sup> or CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice (50). Splenocytes were initially enriched for CD11c<sup>+</sup> cells using a MACS LS column (Miltenyi Biotec, Bergisch Gladbach, Germany) after surface-staining with PE-conjugated anti-CD11c mAb according to the manufacturer's instructions. Enriched CD11c<sup>+</sup> cells were then applied to a FACS sorter to purify CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs. Purified CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs (5 × 10<sup>5</sup> cells/mouse, 50 μl) were injected into left and right footpads of CX<sub>3</sub>CR1<sup>-/-</sup> mice, respectively. CX<sub>3</sub>CR1<sup>-/-</sup> recipients were immediately infected with JEV (5.0 × 10<sup>7</sup> PFU) via footpad, and leukocytes were obtained from left and right popliteal LNs at 3 dpi. Popliteal LN cells were surface-stained with PE-conjugated anti-mouse CD11c for CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup> CD11c<sup>+</sup>

DCs. In some challenge experiments, purified CD11c<sup>+</sup> DCs (1.5 × 10<sup>6</sup> cells, 250 μl) were injected i.v. into CX<sub>3</sub>CR1<sup>-/-</sup> mice. Flow cytometric analysis was performed using a FACS Calibur flow cytometer (Becton Dickson Medical Systems) with FlowJo software (Tree Star).

## CFSE Cell Division Assay in Peripheral LNs

Ag-specific CD4<sup>+</sup> T cell responses in popliteal LNs were assessed by CFSE cell division following footpad injection of CX<sub>3</sub>CR1<sup>+/gfp</sup> or CX<sub>3</sub>CR1<sup>gfp/gfp</sup> CD11c<sup>+</sup> DCs. Briefly, OVA<sub>323–339</sub>-specific CD4<sup>+</sup> T cells were purified from OT-II mice using a MACS LS column (Miltenyi Biotec), according to the manufacturer's instructions. Purified OT-II CD4<sup>+</sup> T cells were labeled with 2.5 μM CFSE and adoptively transferred into CX<sub>3</sub>CR1<sup>-/-</sup> mice (1 × 10<sup>6</sup> cells/mouse) injected with CX<sub>3</sub>CR<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup> CD11c<sup>+</sup> DCs in the left and the right footpads, respectively. Three days following infection of CX<sub>3</sub>CR1<sup>-/-</sup> recipients with recombinant vaccinia virus expressing OVA (1 × 10<sup>6</sup> PFU/mouse) via footpad route, leukocytes were obtained from left and right popliteal LNs of the recipients and subjected to surface-staining for CD4 and Vα2 using PE-conjugated anti-mouse CD4 and PerCP-conjugated anti-mouse Vα2. Flow cytometric analysis was performed on a FACS Calibur flow cytometer (Becton Dickson Medical Systems) with FlowJo software (Tree Star).

## Statistical Analysis

All data were expressed as average ± standard error of the mean (SEM). Statistically significant differences between groups were analyzed using an unpaired two-tailed Student's *t*-test for *ex vivo* experiments and immune cell analysis. For multiple comparisons, statistical significance was determined using one-way or two-way analysis of variance (ANOVA) with repeated measures followed by Bonferroni *post-hoc* tests. Statistical significance of viral burden and *in vivo* cytokine gene expression were evaluated by Mann-Whitney test or unpaired two-tailed Student's *t*-test. Kaplan-Meier survival curves were analyzed by log-rank test. A *p* ≤ 0.05 was considered significant. All data were analyzed using GraphPadPrism4 software (GraphPad Software, Inc., San Diego, CA, USA).

## RESULTS

### Essential Role of CX<sub>3</sub>CR1 in Conferring Resistance to JEV Following Local, but Not Systemic Infection


To investigate the relevance of CX<sub>3</sub>CR1 in JE progression, we infected CX<sub>3</sub>CR1-competent and -deficient mice (CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup>, respectively) with JEV via footpad, intranasal, and intraperitoneal routes. We then compared the susceptibilities of both strains to JE progression. Our data revealed that the ablation of CX<sub>3</sub>CR1 resulted in markedly enhanced susceptibility to JE, with mortality of around 80% after JEV infection via footpad inoculation compared to 10% mortality in CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 1A**, *left graph*). In contrast, both CX<sub>3</sub>CR1-competent and deficient mice all succumbed to JE progression following intranasal inoculation of JEV infection,

although the survival of CX<sub>3</sub>CR1<sup>+/+</sup> mice was moderately prolonged (**Figure 1A, middle graph**). A mortality of 80% was observed among CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice exposed to intraperitoneal inoculation of JEV infection (**Figure 1A, right graph**). These results indicate that CX<sub>3</sub>CR1-ablated mice were highly susceptible to JE progression only after JEV inoculation via footpad route. In support of this finding, the CX<sub>3</sub>CR1<sup>-/-</sup> mice showed a rapid and higher proportion of neurological disorders starting at 4–5 dpi, compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice that displayed the delayed signs of neurological disorder around 6–7 days after footpad inoculation of JEV (**Figure 1B, left graph**). However, the proportions of CX<sub>3</sub>CR1<sup>-/-</sup> mice showing neurological disorder were similar to those of CX<sub>3</sub>CR1<sup>+/+</sup> mice following intranasal and intraperitoneal inoculation with JEV (**Figure 1B, middle and right graphs**). Furthermore, CX<sub>3</sub>CR1<sup>-/-</sup> mice scored higher for clinical signs of encephalitis than CX<sub>3</sub>CR1<sup>+/+</sup> mice after peripheral JEV inoculation (**Figure 1C, left graph**). In contrast, CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice showed similar kinetics for encephalitis score after intranasal and intraperitoneal inoculation, although CX<sub>3</sub>CR1<sup>-/-</sup> mice showed rapid clinical signs of encephalitis compared with CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 1C, middle and right graphs**). CX<sub>3</sub>CR1 ablation resulted in marked changes in body weight during JE progression following footpad inoculation of JEV. However, CX<sub>3</sub>CR1<sup>-/-</sup> and CX<sub>3</sub>CR1<sup>+/+</sup> mice showed similar reductions in body weight after intranasal and intraperitoneal JEV administration, except that CX<sub>3</sub>CR1<sup>-/-</sup> mice showed a slightly higher reduction in body weight at a later stage after intranasal exposure to JEV compared with CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 1D**). Similarly, CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice with green fluorescent protein (GFP) inserted into two alleles of CX<sub>3</sub>CR1 locus showed highly increased susceptibility to JE progression only after peripheral inoculation of JEV via footpad, compared to CX<sub>3</sub>CR1<sup>+/gfp</sup> mice (Data not shown). To better understand the severity of JE progression in CX<sub>3</sub>CR1<sup>-/-</sup> mice following peripheral JEV inoculation, we performed histopathological analysis of brains derived from CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice after JEV inoculation via footpad, intranasal, and intraperitoneal routes. As expected, CX<sub>3</sub>CR1<sup>+/+</sup> mice showed reduced inflammation involving blood vessels, meninges, and ventricles in the brain compared with CX<sub>3</sub>CR1<sup>-/-</sup> mice exposed to JEV inoculation via footpad, based on CNS infiltration of peripheral leukocytes (**Figure 2A**). However, CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice showed comparable levels of neuroinflammation after intranasal and intraperitoneal inoculation of JEV. CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice displayed higher peripheral leukocyte infiltration of inflammatory areas after JEV inoculation via intranasal and intraperitoneal routes, compared with CX<sub>3</sub>CR1<sup>+/+</sup> mice infected via footpad. Enhanced infiltration of CD11b<sup>+</sup> myeloid cells in the brain of CX<sub>3</sub>CR1<sup>-/-</sup> mice was further confirmed by immunohistochemistry using anti-CD11b mAb, after JEV inoculation via footpad (**Figure 2B**). In contrast, CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice showed no apparent differences in infiltration of CD11b<sup>+</sup> cells after JEV inoculation via intranasal and intraperitoneal routes. Taken together, our results clearly suggest that CX<sub>3</sub>CR1 ablation leads to severely exacerbated JE progression following peripheral inoculation

of JEV, although CX<sub>3</sub>CR1 is dispensable for the control of JE progression upon systemic viral inoculation.

## CX<sub>3</sub>CR1 Regulates Neuroinflammation Following Local JEV Infection

JE is a lethal neuroinflammation characterized by extensive CNS infiltration of myeloid-derived cells including Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes (51). Notably, Ly-6C<sup>hi</sup> monocytes migrate into the infected brain followed by differentiation into DCs, macrophages, and microglia (52, 53). Although the potential contribution of Ly-6C<sup>hi</sup> monocytes to neuroinflammation remains controversial, CNS infiltration of Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes may contribute to the pathophysiology of lethal neuroinflammation (54). To further characterize the exacerbation of JE in CX<sub>3</sub>CR1-ablated mice following peripheral JEV inoculation via footpad, we analyzed CNS infiltration of myeloid-derived cell subsets including monocytes and granulocytes during JE progression. The CX<sub>3</sub>CR1<sup>-/-</sup> mice showed increased infiltration of Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes into the brain compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 3A**). The CNS infiltration of Ly-6C<sup>hi</sup> monocytes in CX<sub>3</sub>CR1<sup>-/-</sup> mice peaked at 3 dpi and declined subsequently whereas the frequency of Ly-6G<sup>hi</sup> granulocytes in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice increased eventually depending on JE progression. CD11b<sup>+</sup> myeloid cells infiltrating into the brain comprised four subpopulations (G1: Ly-6C<sup>lo</sup>Ly-6G<sup>hi</sup>, G2: Ly-6C<sup>hi</sup>Ly-6G<sup>lo</sup>, G3: Ly-6C<sup>int</sup>Ly-6G<sup>lo</sup>, and G4: Ly-6C<sup>lo</sup>Ly-6G<sup>lo</sup>) depending on the expression of Ly-6C and Ly-6G (**Figure 3B**). To delineate JE progression in CX<sub>3</sub>CR1<sup>-/-</sup> mice, we enumerated subpopulations of CNS-infiltrated CD11b<sup>+</sup> myeloid cells including Ly-6C<sup>hi</sup>Ly-6G<sup>lo</sup> monocytes and Ly-6C<sup>lo</sup>Ly-6G<sup>hi</sup> granulocytes. CX<sub>3</sub>CR1-ablated mice harbored a significantly higher number of total CD11b<sup>+</sup> myeloid cells in the brain during the examination period (0–4 dpi) compared with CX<sub>3</sub>CR1-competent mice (**Figure 3B**). Similarly, CX<sub>3</sub>CR1 ablation strongly increased CNS infiltration of all the CD11b<sup>+</sup> subpopulations including Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes with saturated levels at 3 dpi. Notably, Ly-6G<sup>hi</sup> granulocytes were gradually accumulated in the brains of CX<sub>3</sub>CR1<sup>-/-</sup> mice with a markedly higher level, compared to the CX<sub>3</sub>CR1<sup>+/+</sup> mice until 4 dpi. It has been reported that microglia contribute to the pathogenesis of encephalitis caused by neurotrophic viruses such as West Nile virus (55) and CNS-infiltrated Ly-6C<sup>hi</sup> monocytes are differentiated into inflammatory macrophages such as microglia (55). Ly-6C<sup>int</sup>Ly-6G<sup>lo</sup> and Ly-6C<sup>lo</sup>Ly-6G<sup>lo</sup> subpopulations in CD11b<sup>+</sup> myeloid cells may comprise activated microglia cells (56). Therefore, we further examined the changes of resting and activated microglia in the brain based on the expression of Tmem119, a microglia-specific marker (57). As shown in **Figure 3C**, CX<sub>3</sub>CR1 ablation strongly increased the frequency of CD11b<sup>+</sup>CD45<sup>hi</sup>Tmem119<sup>int</sup> activated microglia (6.57%) 4 dpi compared with those in CX<sub>3</sub>CR1<sup>+/+</sup> mice (0.96%). In addition, CX<sub>3</sub>CR1<sup>-/-</sup> mice contained accumulated number of CD11b<sup>+</sup>CD45<sup>hi</sup>Tmem119<sup>int</sup> activated microglia in the CNS with markedly higher levels up to 4 dpi, compared to CX<sub>3</sub>CR1<sup>+/+</sup>




**FIGURE 1 |** CX<sub>3</sub>CR1 is indispensable for the regulation of JE following local inoculation of virus. **(A)** Susceptibility of CX<sub>3</sub>CR1-ablated mice to JE. Wild-type (CX<sub>3</sub>CR1<sup>+/+</sup>) and CX<sub>3</sub>CR1-deficient (CX<sub>3</sub>CR1<sup>-/-</sup>) mice (5–6 weeks old,  $n = 10–13$ ) were inoculated with JEV ( $5.0 \times 10^7$  PFU) via footpad, intranasal, and

(Continued)



**FIGURE 1** | intraperitoneal routes. The proportion of surviving mice in each group was monitored daily for 15 or 20 days. **(B)** Ratio of mice showing neurological disorder during JE progression. Mice infected with JEV were examined every 6 h from 4 to 15 dpi and the ratio of mice showing neurological disorder in inoculated mice was recorded. Blue arrows denote a time point of neurological disorder manifestation following JEV infection. **(C)** Encephalitis score. Mice infected with JEV were scored for encephalitis from 3 to 12 dpi. Encephalitis scores were expressed as average score  $\pm$  SEM of each group. **(D)** Changes in body weight. Changes in body weight were expressed as the average percentage  $\pm$  SEM of body weight relative to the time of challenge. \* $p < 0.05$ ; \*\* $p < 0.01$ ; and \*\*\* $p < 0.001$  for levels between CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice at indicated dpi.




**FIGURE 2** | Histopathological analysis supports severe neuroinflammation in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice. **(A)** Brain sections of CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice were prepared and stained with H&E 5 days after JEV infection via footpad, intranasal, and intraperitoneal inoculation. Representative photomicrographs of the brain were obtained from blood vessel areas, meninges, and ventricles. **(B)** Detection of infiltrated CD11b<sup>+</sup> myeloid cells in the brain. Brain sections prepared from CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice were used for the detection of CD11b<sup>+</sup> myeloid cells by staining with anti-CD11b mAb. CD11b<sup>+</sup> cells were detected in cortical parenchyma area of the brain. Images are representative of sections (200 $\times$ ) derived from at least four mice. Interest areas infiltrated with leukocytes are denoted by black arrows.

mice (**Figure 3D**). CD11b<sup>+</sup>CD45<sup>int</sup>Tmem119<sup>hi</sup> resting microglia were also detected in CNS tissues of CX<sub>3</sub>CR1<sup>-/-</sup> mice with increased levels at 3 dpi compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice (10.8 vs. 4.24%). This indicates that CX<sub>3</sub>CR1 ablation increased both activated and resting microglia during JE progression.

In terms of severe neuroinflammation involving CX<sub>3</sub>CR1<sup>-/-</sup> mice following peripheral JEV inoculation via footpad, the expression of cytokines and chemokines within the CNS may further explain encephalitis because neuroinflammation triggered by neurotrophic viruses is indirectly attributed to CNS degeneration by robust immunological responses such as uncontrolled secretion of cytokines and chemokines and the activation of microglia and astrocytes (10, 11, 58). Therefore, we examined the expression of cytokines and chemokines in the CNS. Our results revealed that peripheral JEV inoculation

of CX<sub>3</sub>CR1<sup>-/-</sup> mice strongly increased the expression of TNF- $\alpha$  and IL-6 with peak levels detected at 4 dpi compared with CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 3E**). CC chemokines CCL2 and CCL3 were expressed at higher levels (peaks at 2 dpi) in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice compared with those of CX<sub>3</sub>CR1<sup>+/+</sup> mice whereas CXC chemokines CXCL1 and CXCL2 showed prolonged and higher expression in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice until 4 dpi. These results indicate that sequential and uncontrolled expression of cytokines and CC/CXC chemokines might result in severe neuroinflammation in CX<sub>3</sub>CR1<sup>-/-</sup> mice via infiltration of Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes and microglial activation. To further characterize the severity of neuroinflammation in CX<sub>3</sub>CR1<sup>-/-</sup> mice, we measured the levels of systemic IL-6 and TNF- $\alpha$ . A trend toward rapid induction and increased levels of serum IL-6 and TNF- $\alpha$





in CX<sub>3</sub>CR1<sup>-/-</sup> mice compared with CX<sub>3</sub>CR1<sup>+/+</sup> mice was observed (Figure 3F). Taken together, these results demonstrate that robust inflammatory cytokine and chemokine responses drive the severity of neuroinflammation in CX<sub>3</sub>CR1<sup>-/-</sup> mice.

### Delayed Viral Clearance in Peripheral Lymphoid Tissues Is Closely Associated With JE Exacerbation in CX<sub>3</sub>CR1<sup>-/-</sup> Mice

Neurotrophic viruses such as WNV and JEV are thought to replicate in keratinocytes and cutaneous DCs and Langerhans cells following inoculation at peripheral sites such as footpad (59–61). Infected DCs migrate to regional dLNs and seed the

virus within these dLNs (59–61). Replication within dLNs leads to primary viremia and subsequent dissemination of infection to permissive organs (such as the spleen) and non-permissive organs (such as kidney and liver) (62). In general, viral replication peaks in the spleen and the serum by 3–4 dpi. Subsequently, viruses are cleared by host defense responses between 6 and 8 dpi (61). However, delayed clearance of infectious virus at peripheral sites by inappropriate host defense may generate large viral loads for CNS invasion. Therefore, we examined the viral burden in dLNs (popliteal LNs), susceptible organs (spleen), sera, and the CNS kinetically during JE progression, in order to elucidate the process of severe neuroinflammation in CX<sub>3</sub>CR1<sup>-/-</sup> mice following peripheral JEV inoculation via footpad. Somewhat

surprisingly, wild-type CX<sub>3</sub>CR1<sup>+/+</sup> mice carried a higher viral burden in the popliteal LNs and spleen at an early stage until 3–4 dpi compared to CX<sub>3</sub>CR1-ablated mice. Then, these viruses were rapidly cleared at peripheral sites (Figure 4A). However, CX<sub>3</sub>CR1-ablated mice showed a 10- to 100-fold lower viral burden in popliteal LNs and spleen at early stage compared to wild-type mice. Subsequently, viral burden gradually increased depending on JE progression. Ultimately, the CX<sub>3</sub>CR1-ablated mice carried higher viral burdens in popliteal LNs and spleen at late stages compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice. Due to high viral burden in peripheral lymphoid tissues of CX<sub>3</sub>CR1<sup>-/-</sup> mice, CX<sub>3</sub>CR1<sup>-/-</sup> mice showed higher levels of infectious JEV in sera and viral burden in the brain than CX<sub>3</sub>CR1<sup>+/+</sup> mice (Figure 4B). Notably, CX<sub>3</sub>CR1<sup>-/-</sup> mice were observed to contain viral burden in brain with around 1,000-fold increased level during JE progression, compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice. In addition, CX<sub>3</sub>CR1-ablated mice showed a sharp increase in viral burden in the CNS at around 3 dpi, the time point that high viral burden in peripheral lymphoid tissues of CX<sub>3</sub>CR1<sup>+/+</sup> mice was rapidly decreased. It is thought that JEV inoculated via footpad may be translocated along with infected DCs into dLNs (popliteal LNs) (61). Therefore, we performed confocal microscopy to detect JEV Ags along with DCs in popliteal LNs at the early stage. Viral Ags were detected in the popliteal LNs of CX<sub>3</sub>CR1<sup>+/gfp</sup> mice with an apparently higher frequency in popliteal LNs at the early stage (2 dpi) compared to CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice (Figure 4C, upper and lower pictures). Viral Ags were mostly detected within interfollicular and sinus adjacent area near germinal center (Figure 4C, upper pictures). Notably, many JEV Ags were colocalized with CX<sub>3</sub>CR1<sup>+</sup> DCs in interfollicular and T-cell zone in popliteal LNs of CX<sub>3</sub>CR1<sup>+/gfp</sup> mice. In contrast, JEV Ags were detected in the brains of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice with a high frequency at the late stage (5 dpi) compared to the brains of CX<sub>3</sub>CR1<sup>+/gfp</sup> mice (Figure 4D). Collectively, these results suggest that CX<sub>3</sub>CR1 plays an important role in the rapid influx of JEV in dLNs (popliteal LNs) at early stage following viral inoculation via footpad. It also plays an important role in viral clearance in the peripheral lymphoid tissues and the CNS at later stage.


### CX<sub>3</sub>CR1 Is Essential for Antiviral NK Cell Activation and Ag-Specific T-Cell Response in dLNs

Antiviral immunity including NK cell activation and JEV-specific T-cell responses is believed to play an important role in regulating JE progression via JEV control and clearance from extraneural tissues (8, 9, 15). The CX<sub>3</sub>CR1-ablated mice showed an impaired clearance of footpad-inoculated JEV in dLNs. Therefore, we compared NK-cell and JEV-specific T-cell responses in popliteal LNs of both wild-type CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice following footpad JEV inoculation. Both CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice contained comparable numbers of CD3<sup>-</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells in popliteal LNs with increased levels at 24 and 48 h after JEV infection compared to mock-infected mice (Figure 5A). However, CX<sub>3</sub>CR1<sup>-/-</sup> mice exhibited markedly reduced NK cell activation in popliteal

LNs based on the production of IFN- $\gamma$  and granzyme B from CD3<sup>-</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells in response to brief stimulation with PMA and ionomycin (Figure 5B). Similarly, CX<sub>3</sub>CR1<sup>-/-</sup> mice carried significantly reduced numbers of IFN- $\gamma$  or granzyme B-producing NK cells in popliteal LNs (Figure 5C). These results indicate that CX<sub>3</sub>CR1 plays an important role in activating NK cells in dLNs following footpad challenge with JEV. Furthermore, we examined JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in popliteal LNs of surviving CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice at 5 dpi. CX<sub>3</sub>CR1 ablation resulted in significant reduction of JEV-specific CD4<sup>+</sup> T-cell responses when CD4<sup>+</sup> T-cell responses were evaluated by intracellular CD154 and IFN- $\gamma$  staining in response to stimulation with CD4<sup>+</sup> T-cell epitope peptide (NS3<sub>563–574</sub>) (Figure 5D). Consistent with this finding, total number of CD154<sup>+</sup> and IFN- $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells was found to be significantly decreased in popliteal LNs of CX<sub>3</sub>CR1-ablated mice (Figure 5E). CX<sub>3</sub>CR1-ablated mice also showed reduced numbers of CD8<sup>+</sup> T cells, based on IFN- $\gamma$  and TNF- $\alpha$  responses after stimulation with CD8<sup>+</sup> T-cell epitope peptide (NS4B<sub>215–223</sub>) (Figures 5F,G). In order to further understand that CX<sub>3</sub>CR1 ablation results in impaired NK and T-cell responses, we used a selective, high-affinity inhibitor of CX<sub>3</sub>CR1 (AZD8797) (63). CX<sub>3</sub>CR1<sup>+/+</sup> wild-type mice were intravenously treated with AZD8797 prior to JEV infection. CX<sub>3</sub>CR1 inhibitor were daily injected to CX<sub>3</sub>CR1<sup>+/+</sup> mice till analysis date. CX<sub>3</sub>CR1 inhibitor-treated mice displayed highly decreased activation of NK cells in popliteal LNs following JEV inoculation via footpad (Supplementary Figure 1A). Similarly, CX<sub>3</sub>CR1<sup>+/+</sup> mice showed impaired JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses after treatment with AZD8797 (Supplementary Figures 1B,C), which indicates that functional inhibition of CX<sub>3</sub>CR1 results in impaired generation of NK and JEV-specific T-cell responses in peripheral lymphoid tissues following peripheral JEV inoculation. In addition, we monitored the activation of NK cells in blood during JE progression. As expected, CX<sub>3</sub>CR1<sup>-/-</sup> mice showed decreased activation of blood NK cells compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice (Supplementary Figure 2A). Also, CX<sub>3</sub>CR1<sup>-/-</sup> mice appeared to accumulate lower frequency and number of JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the brain, compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice (Supplementary Figure 2B). However, our data revealed that CX<sub>3</sub>CR1 ablation induced no significant changes in serum IgM or IgG specific for JEV antigen (Figure 5H). This finding indicates that CX<sub>3</sub>CR1 plays no significant role in regulating humoral immune responses specific for JEV Ags. Collectively, these results suggest that CX<sub>3</sub>CR1 plays an important role in NK cell activation and generation of JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell response in dLNs following peripheral JEV inoculation.

### CX<sub>3</sub>CR1-Ablated Mice Show Impaired Accumulation of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs and CX<sub>3</sub>CR1<sup>+</sup>CD11b<sup>hi</sup> Myeloid Cells in dLNs


CX<sub>3</sub>CR1 and its ligand CX<sub>3</sub>CL1 contribute to immune cell recruitment during inflammation via either chemotaxis or adhesion because the CX<sub>3</sub>CR1-CX<sub>3</sub>CL1 axis is known to play a



role in the migration of NK cells, T cells, monocytes, and mast cells (29). CX<sub>3</sub>CR1 ablation failed to alter the total number of CD45<sup>+</sup> leukocytes in popliteal LNs following JEV infection via footpad inoculation (**Figure 6A**). Notably, both CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice showed rapid and comparable increase in leukocyte levels in dLNs from 2 dpi. Also, CD11c<sup>+</sup> and CD11b<sup>+</sup> myeloid cells were detected in popliteal LNs of CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice with comparable levels 5 dpi (**Figure 6B**). These data indicate that CX<sub>3</sub>CR1 ablation did not affect the migration of CD45<sup>+</sup> leukocytes as well as CD11c<sup>+</sup> and CD11b<sup>+</sup> myeloid cells. CX<sub>3</sub>CR1 is expressed on several types of leukocytes, including monocytes, T-cell subsets, NK cells, microglia, neurons, astrocytes, and platelets (30–35).

To delineate the leukocyte subpopulation whose migration is affected by CX<sub>3</sub>CR1 during JE progression, we examined the expression of CX<sub>3</sub>CR1 in various subsets of immune cells recruited in popliteal LNs and footpad following footpad inoculation of JEV. As a result, we found that CD11b<sup>+</sup> and CD11c<sup>+</sup> myeloid cell populations showed constitutive expression of CX<sub>3</sub>CR1 at higher levels compared to other immune cells, including NK cells, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells (**Figure 6C**). The CX<sub>3</sub>CR1 expression in CD11b<sup>+</sup> and CD11c<sup>+</sup> cells derived from footpad and popliteal LNs was strongly increased following JEV infection. In support, CX<sub>3</sub>CR1<sup>+</sup> cells in CD11c<sup>+</sup> and CD11b<sup>+</sup> myeloid cell populations were more accumulated in popliteal LNs compared to other immune cells (**Figure 6D**). The





CD11b<sup>+</sup> and CD11c<sup>+</sup> myeloid cells mainly include antigen-presenting cells such as CD11b<sup>+</sup>CD11c<sup>+</sup> myeloid DCs (64, 65). CX<sub>3</sub>CR1<sup>-/-</sup> mice showed impaired NK cell activation and JEV-specific T-cell responses. Indeed, CX<sub>3</sub>CR1-positive cells in CD11b<sup>+</sup>CD11c<sup>+</sup> DC population were likely to be recruited into popliteal LNs at 2 days following footpad inoculation of JEV (**Figure 6C**). Therefore, we examined the kinetics of migration of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs and CD11b<sup>+</sup> myeloid cells into popliteal LNs of CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice following footpad inoculation. CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice displayed markedly impaired recruitment of CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>hi</sup> and CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>int</sup> DCs in popliteal LNs following

footpad challenge (**Figure 6E**). Similarly, CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice accumulated a lower number of CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>hi</sup> and CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>int</sup> DCs in popliteal LNs during JE progression compared to CX<sub>3</sub>CR1<sup>+/gfp</sup> mice (**Figure 6F**). Notably, CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>hi</sup> DCs were detected with very low levels in popliteal LNs of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice. Consistent with impaired recruitment of CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>hi</sup> DCs in CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice, the recruitment of CX<sub>3</sub>CR1<sup>gfp</sup>CD11b<sup>hi</sup> and CD11b<sup>int</sup> myeloid cells into the popliteal LNs of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice was delayed (**Figures 6G,H**). However, the total numbers of CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>lo</sup> and CD11b<sup>lo</sup> cells were comparable between CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>



mice, suggesting that the recruitment of CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>lo</sup> and CD11b<sup>lo</sup> cells was unlikely to depend on the CX<sub>3</sub>CR1-CX<sub>3</sub>CL1 axis. In support, treatment with CX<sub>3</sub>CR1 inhibitor resulted in delayed accumulation of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> and CD11c<sup>int</sup> DCs in popliteal LNs following JEV inoculation via footpad, while migration of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>lo</sup> cells was not affected by CX<sub>3</sub>CR1 inhibitor (**Supplementary Figure 3A**). Accumulation of CX<sub>3</sub>CR1<sup>+</sup>CD11b<sup>hi</sup> and CD11b<sup>int</sup> myeloid cells was also reduced by treatment of CX<sub>3</sub>CR1 inhibitor (**Supplementary Figure 3B**). Collectively, these results indicate that functional inhibition of CX<sub>3</sub>CR1 results in the impaired recruitment of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs and CX<sub>3</sub>CR1<sup>+</sup>CD11b<sup>+</sup> myeloid cells into the dLNs following footpad inoculation of JEV. In particular, impaired recruitment of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs into dLNs of CX<sub>3</sub>CR1<sup>-/-</sup> mice appears to decrease NK cell activation and JEV-specific T-cell response, compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice.


### CX<sub>3</sub>CR1-Ablated DCs Exhibit Delayed and Reduced NK-Cell Activation and CD4<sup>+</sup>/CD8<sup>+</sup> T Cell Response in dLNs

It has been reported that CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice with GFP inserted into two alleles of the CX<sub>3</sub>CR1 locus show no functional expression of CX<sub>3</sub>CL1 receptor. However, all surface CX<sub>3</sub>CR1-positive cells in heterozygous CX<sub>3</sub>CR1<sup>+/gfp</sup> mice show GFP expression as well as biallelic functional expression of CX<sub>3</sub>CL1 receptor (50). It is believed that CD11c<sup>+</sup> DCs play a crucial role in activating NK cells via NK-DC crosstalk and in initiating Ag-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses (66). However, our results provided no direct evidence that delayed recruitment of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs resulted in the impaired NK cell activation and JEV-specific T-cell responses in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> mice. To directly demonstrate the role of delayed CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DC recruitment in impaired NK cell activation and T-cell responses, the CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>+</sup> DCs were purified from the spleens of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> or CX<sub>3</sub>CR1<sup>+/gfp</sup> mice and subsequently injected into footpads of CX<sub>3</sub>CR1<sup>-/-</sup> mice. We then examined NK cell activation in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipient mice at 2 days following immediate JEV infection via footpad inoculation. CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/gfp</sup> or CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs showed comparable frequencies of CD3<sup>-</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells in popliteal LNs following footpad inoculation of JEV (**Figure 7A**). However, CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs showed markedly reduced activation of NK cells compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs, when NK cell activation was evaluated by IFN-γ and granzyme B production in response to brief stimulation by PMA and ionomycin. CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs also carried comparable numbers of NK cells in popliteal LNs. However, footpad injection of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs into CX<sub>3</sub>CR1<sup>-/-</sup> mice resulted in a significant reduction of IFN-γ and granzyme B-producing NK cells compared to CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs (**Figure 7B**). Furthermore, we examined the JEV-specific CD4<sup>+</sup>

and CD8<sup>+</sup> T-cell responses in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs at 7 days after footpad inoculation of JEV. CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs showed lower responses of CD4<sup>+</sup> T cells specific for JEV Ag compared to CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs, based on frequencies of CD154<sup>+</sup>, IFN-γ<sup>+</sup>, and TNF-α<sup>+</sup> cells in CD4<sup>+</sup> T cells stimulated with CD4<sup>+</sup> T-cell epitope (NS3<sub>563-574</sub>) (**Figure 7C**). Similarly, CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs harbored significantly decreased numbers of JEV-specific CD4<sup>+</sup> T cells in popliteal LNs compared to CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs (**Figure 7D**). Consistent with the weak response of JEV-specific CD4<sup>+</sup> T cells in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs, footpad injection of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs induced a lower level of JEV-specific CD8<sup>+</sup> T cell response in popliteal LNs compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs (**Figures 7E,F**). Ultimately, these results indicate that functional deficiency of CX<sub>3</sub>CR1 expression in CD11c<sup>+</sup> DCs leads to impaired NK cell activation and reduced the generation of JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell response in dLNs following footpad injection.

### CX<sub>3</sub>CR1-Ablated DCs Show Delayed Initiation of Ag-Specific CD4<sup>+</sup> T-Cell Responses in dLNs

Because impaired NK cell activation and JEV-specific T-cell responses were observed in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients injected with CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs, we determined whether functional deficiency of CX<sub>3</sub>CR1 expression affected their migration from injection site (footpad) to popliteal LNs following JEV infection, resulting in impaired NK cell activation and JEV-specific T-cell responses. CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs were sorted from spleens of heterozygous CX<sub>3</sub>CR1<sup>+/gfp</sup> and homozygous CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice, and injected into left and right footpads of CX<sub>3</sub>CR1<sup>-/-</sup> mice, respectively. Recruitment of CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients was then observed at 3 days after footpad inoculation of JEV. Our results revealed that functional deficiency of CX<sub>3</sub>CR1 expression delayed the migration of CD11c<sup>+</sup> DCs from the footpad to popliteal LNs, as the lower frequency of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs was observed in popliteal LNs of the right footpad injected with CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs compared to popliteal LNs of the left footpad injected with CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs (**Figure 8A**). However, CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs recruited in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients showed similar expression of phenotype markers including CD80, CD86, MHC I, and MHC II (**Figure 8B**). Also, JEV Ags showed similar levels in CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs derived from the popliteal LNs of left and right footpads, respectively (**Figure 8C**). These data indicate that functional deficiency of CX<sub>3</sub>CR1 expression affected their migration from infection site to dLNs, but not phenotypic changes and JEV infectivity at the peripheral site. Therefore, the delayed delivery of JEV Ags by



**FIGURE 6 |** Impaired accumulation of CX<sub>3</sub>CR1<sup>+</sup> DCs and CD11b<sup>+</sup> myeloid cells in peripheral lymphoid tissues of CX<sub>3</sub>CR1-ablated mice. **(A)** Total leukocyte number in popliteal LNs. Leukocytes were obtained from popliteal LNs of CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice, and used in the analysis of total CD45<sup>+</sup> leukocyte levels at the *(Continued)*

**FIGURE 6** | indicated dpi. **(B)** Analysis of CD11c<sup>+</sup> and CD11b<sup>+</sup> myeloid cell population. The proportion of CD11c<sup>+</sup> and CD11b<sup>+</sup> myeloid cells was determined by flow cytometric analysis using leukocytes obtained from popliteal LNs of CX<sub>3</sub>CR1<sup>+/+</sup> and CX<sub>3</sub>CR1<sup>-/-</sup> mice 5 dpi. **(C)** CX<sub>3</sub>CR1 expression in leukocyte subpopulations. **(D)** Changes of CX<sub>3</sub>CR1<sup>+</sup> cell number in leukocyte subpopulations. Leukocytes were prepared from footpad and popliteal LNs with collagenase digestion and surface-stained by CX<sub>3</sub>CR1 mAb combined with CD3, CD45, CD11c, CD11b, CD4, CD8, DX5, and NK1.1 mAbs at 0 and 2 dpi. Values in histograms denote the average percentage ± SEM of CX<sub>3</sub>CR1-positive cells in indicated leukocyte subpopulations, including CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>-</sup>NK1.1<sup>+</sup>DX5<sup>+</sup>, CD45<sup>+</sup>CD11b<sup>+</sup>, CD45<sup>+</sup>CD11c<sup>+</sup>, and CD45<sup>+</sup>CD11b<sup>+</sup>CD11c<sup>+</sup> cells. **(E,F)** Delayed accumulation of CX<sub>3</sub>CR1<sup>gfp</sup> DCs in popliteal LNs of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice. Leukocytes were obtained from popliteal LNs via collagenase digestion at the indicated dpi and used to determine CX<sub>3</sub>CR1<sup>gfp</sup> DC subsets (CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>hi</sup>, CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>int</sup>) and CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>lo</sup> cells through flow cytometric analysis, after infecting CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice with JEV via footpad inoculation. **(G,H)** Impaired accumulation of CX<sub>3</sub>CR1<sup>gfp</sup> myeloid cells in popliteal LNs of CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice. CX<sub>3</sub>CR1<sup>gfp</sup> myeloid cells including CX<sub>3</sub>CR1<sup>gfp</sup>CD11b<sup>hi</sup> and CX<sub>3</sub>CR1<sup>gfp</sup>CD11b<sup>int</sup> cells in popliteal LNs were counted by flow cytometric analysis from 1 to 7 dpi. Values in representative dot-plots denote the average ± SEM percentage of the indicated cell population after gating on CD45<sup>+</sup> cells, while bar charts show the average ± SEM of values derived from at least three independent experiments ( $n = 4-5$ ). \* $p < 0.05$ ; \*\* $p < 0.01$ ; and \*\*\* $p < 0.001$  for CX<sub>3</sub>CR1<sup>+/+</sup> vs. CX<sub>3</sub>CR1<sup>-/-</sup> mice at indicated dpi.

functional CX<sub>3</sub>CR1 deficiency in CD11c<sup>+</sup> DCs could induce delayed and weak JEV-specific T-cell responses in dLNs. To quantitatively determine this possibility, we used transgenic OT-II CD4<sup>+</sup> T cells that recognize OVA<sub>323-339</sub> epitopes derived from chicken ovalbumin (OVA). The CFSE-labeled OT-II CD4<sup>+</sup> T cells purified from OT-II mice were adoptively transferred into CX<sub>3</sub>CR1<sup>-/-</sup> mice, followed by footpad inoculation with vaccinia virus expressing OVA after injection of CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs into the left and right footpads, respectively. It was found that OT-II CD4<sup>+</sup> T cells in popliteal LNs of the left footpad injected with CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs proliferated rapidly compared to OT-II CD4<sup>+</sup> T cells in popliteal LNs of the right footpad injected with CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs (**Figure 8D**). In addition, total mitotic events of OT-II CD4<sup>+</sup> T cells occurring in popliteal LNs (67) showed a 4-fold increase in the OT-II CD4<sup>+</sup> T cells of popliteal LNs in the left footpad injected with CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs compared to OT-II CD4<sup>+</sup> T cells of popliteal LNs in the right footpad injected with CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs (**Figure 8E**). These results suggest that the rapid Ag-specific T cell response in dLNs is mediated via functional expression of CX<sub>3</sub>CR1 in CD11c<sup>+</sup> DCs.

## Adoptive Transfer of CX<sub>3</sub>CR1<sup>+</sup> DCs Ameliorates JE


A functional deficiency of CX<sub>3</sub>CR1 expression in CD11c<sup>+</sup> DCs abrogated the rapid induction of NK cell activation and JEV-specific T-cell responses, thereby providing enhanced susceptibility to JEV peripheral inoculation. Therefore, we investigated whether adoptive transfer of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs to CX<sub>3</sub>CR1<sup>-/-</sup> mice could restore protection against JEV infection inoculated via footpad. CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs were purified from spleens of wild-type CX<sub>3</sub>CR1<sup>+/+</sup> mice and adoptively transferred into CX<sub>3</sub>CR1<sup>-/-</sup> mice before JEV infection via footpad. Strikingly, CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs showed fully recovered resistance to JE caused by peripheral JEV inoculation. Their resistance levels were comparable to CX<sub>3</sub>CR1<sup>+/+</sup> mice (**Figure 9A**). Adoptive transfer of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs to CX<sub>3</sub>CR1<sup>-/-</sup> recipients strongly enhanced the resistance to JE with a mortality of around 20%, compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice that showed 90% mortality. CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs also showed clinical scores for encephalitis comparable to CX<sub>3</sub>CR1<sup>+/+</sup> wild-type mice whereas CX<sub>3</sub>CR1<sup>-/-</sup> mice

not injected with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs showed a higher encephalitis score (**Figure 9B**). CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs also showed lower changes in body weight compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice (**Figure 9C**). Wild-type CX<sub>3</sub>CR1<sup>+/+</sup> mice showed rapid dissemination of JEV to popliteal LNs and spleens at the early stage following footpad inoculation of JEV. Subsequently, the virus was rapidly cleared. However, CX<sub>3</sub>CR1<sup>-/-</sup> mice showed a gradual increase in viral burden in the dLNs and CNS. Therefore, we kinetically examined the viral burden in dLNs, spleen, and CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice, depending on JE progression. Interestingly, CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs showed elevated viral burdens in popliteal LNs and spleen with levels comparable to wild-type CX<sub>3</sub>CR1<sup>+/+</sup> mice at the early stage, and subsequently the rapid clearance of virus occurred in the peripheral lymphoid tissues eventually (**Figure 9D**). CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs also showed lower viral burdens in the CNS during JE progression compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice. In conclusion, these results indicate that reconstitution of CX<sub>3</sub>CR1<sup>-/-</sup> mice with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs restore protection against peripheral JEV infection.

## Attenuation of JE Progression by Adoptive Transfer of CX<sub>3</sub>CR1<sup>+</sup> DCs

In order to further characterize the neuroinflammation of CX<sub>3</sub>CR1<sup>-/-</sup> recipients injected with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs, we examined CNS infiltration of Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes in CX<sub>3</sub>CR1<sup>-/-</sup> recipients during JE progression. Our results revealed that CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs showed a lower CNS infiltration of Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes following footpad inoculation of JEV compared with CX<sub>3</sub>CR1<sup>-/-</sup> mice (**Figure 10A**). Notably, CNS infiltration of Ly-6C<sup>hi</sup> monocytes was markedly reduced in CX<sub>3</sub>CR1<sup>-/-</sup> recipients injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs, compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice not injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs. Similarly, CX<sub>3</sub>CR1<sup>-/-</sup> recipients injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs showed lower Ly-6C<sup>hi</sup> monocytes and Ly-6G<sup>hi</sup> granulocytes in the CNS compared to CX<sub>3</sub>CR1<sup>-/-</sup> mice (**Figure 10B**). Furthermore, we examined the expression of inflammatory cytokines and chemokines in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> recipients injected with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs. CX<sub>3</sub>CR1<sup>-/-</sup> mice reconstituted with CX<sub>3</sub>CR1<sup>+/+</sup>CD11c<sup>+</sup> DCs showed a diminished expression






**FIGURE 7 |** Delayed and reduced NK cell activation and JEV-specific CD4<sup>+</sup>/CD8<sup>+</sup> T-cell responses by CX<sub>3</sub>CR1-ablated DCs. **(A)** Frequency and activation of NK cells in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CX<sub>3</sub>CR1-ablated DCs. CX<sub>3</sub>CR1<sup>gfp</sup>CD11c<sup>+</sup> DCs from spleens of CX<sub>3</sub>CR1<sup>+/gfp</sup> or CX<sub>3</sub>CR1<sup>gfp/gfp</sup> mice were  
(Continued)



**FIGURE 7** | sorted and injected into CX<sub>3</sub>CR1<sup>-/-</sup> recipient mice via footpad ( $5 \times 10^5$  cells/mouse). CX<sub>3</sub>CR1<sup>-/-</sup> recipients were subsequently infected with JEV via footpad inoculation. Two days following infection, the frequency and activation of NK cells in popliteal LNs were determined by intracellular staining for IFN- $\gamma$  and granzyme B (GrB) along with surface staining for CD3, NK1.1, and DX5 following brief stimulation with PMA and ionomycin. Values in the plots represent the average  $\pm$  SEM of IFN- $\gamma$  or GrB-producing cells in NK1.1<sup>+</sup> cells after gating on CD3<sup>+</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells ( $n = 4-5$ ). Vaginal leukocytes unstimulated with PMA and ionomycin were used for negative control. **(B)** Absolute number of IFN- $\gamma$  or granzyme B-producing CD3<sup>+</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients. **(C,D)** JEV-specific CD4<sup>+</sup> T-cell responses in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients. **(E,F)** JEV-specific CD8<sup>+</sup> T-cell responses in popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipients. At 7 days after JEV infection, leukocytes were obtained from popliteal LNs of CX<sub>3</sub>CR1<sup>-/-</sup> recipient mice injected with CX<sub>3</sub>CR1<sup>+/gfp</sup> or CX<sub>3</sub>CR1<sup>gfp/gfp</sup> DCs and used for stimulation with JEV epitope peptide of CD4<sup>+</sup> T cells (NS3<sub>563-574</sub>) or CD8<sup>+</sup> T cells (NS4B<sub>215-223</sub>) for 12 or 8 h, respectively. The frequency and absolute number of JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were determined by intracellular CD154 and cytokine (IFN- $\gamma$  and TNF- $\alpha$ ) staining combined with surface staining for CD4 and CD8. Values in representative dot-plots represent the average  $\pm$  SEM percentage of the indicated cell population. Bar charts show the average  $\pm$  SEM of values derived from at least three independent experiments ( $n = 4-5$ ). \*\* $p < 0.01$  and \*\*\* $p < 0.001$  comparing the indicated groups.




of cytokines (TNF- $\alpha$ , IL-6) and chemokines (CCL2, CCL3, CXCL1, and CXCL2) in the CNS during JE progression (Figure 10C). These results indicate that reconstitution of CX<sub>3</sub>CR1<sup>-/-</sup> mice with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs ameliorated JE progression.


## DISCUSSION

Our results demonstrate that CX<sub>3</sub>CR1 is essential for the regulation of neuroinflammation in the CNS following peripheral inoculation of JEV infection via footpad, but not intranasal or intraperitoneal inoculation of JEV. Interesting finding in the present study was that CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs were strongly

correlated with increased susceptibility of CX<sub>3</sub>CR1-ablated mice to JE after peripheral JEV inoculation. Several lines of evidence support the essential role of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs in providing resistance to JE. First, the rapid appearance of JEV Ag in dLNs of CX<sub>3</sub>CR1<sup>+/+</sup> mice was closely associated with recruitment of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs, which effectively induced NK cell activation and JEV-specific CD4<sup>+</sup> T-cell responses. In contrast, impaired recruitment of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>hi</sup> DCs delayed and weakened NK cell activation and JEV-specific CD4<sup>+</sup> T cells in dLNs of CX<sub>3</sub>CR1<sup>-/-</sup> mice. Second, using biallelic functional expression system of CX<sub>3</sub>CR1, our results revealed that the functional expression of CX<sub>3</sub>CR1 on CD11c<sup>hi</sup> DCs was required to induce rapid and effective NK cell activation and CD4<sup>+</sup> T-cell



**FIGURE 9 |** Restoration of resistance to JE by adoptive transfer of CX<sub>3</sub>CR1<sup>+</sup> DCs. CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs from spleens of wild-type mice were sorted and adoptively transferred into CX<sub>3</sub>CR1<sup>-/-</sup> mice via tail vein and foot pad inoculation ( $5 \times 10^5$  cells/mouse). CX<sub>3</sub>CR1<sup>-/-</sup> recipients ( $n = 10-11$ ) were subsequently infected with JEV ( $5.0 \times 10^7$  PFU) via footpad inoculation. CX<sub>3</sub>CR1<sup>+/+</sup> wild-type mice and CX<sub>3</sub>CR1<sup>-/-</sup> mice that received no cells were used as positive and negative controls, respectively. **(A)** Susceptibility of CX<sub>3</sub>CR1<sup>-/-</sup> recipients for CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs to JE. The proportion of surviving mice in each group was monitored daily for 20 days. **(B)** Encephalitis score. Mice infected with JEV were scored for encephalitis from 3 to 12 dpi and the encephalitis score was expressed as the average score  $\pm$  SEM of each group. **(C)** Changes in body weight. Changes in body weight were expressed as average percentage  $\pm$  SEM of body weight relative to the time of challenge. **(D)** Viral burden in peripheral lymphoid and CNS tissues of CX<sub>3</sub>CR1<sup>-/-</sup> recipients for CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs during JE progression. The viral burdens in spleen, brain, and spinal cord of CX<sub>3</sub>CR1<sup>-/-</sup> recipients infected with JEV were assessed by real-time qRT-PCR at indicated dpi. Viral RNA load was expressed as viral RNA copy number per microgram of total RNA. Data show the average  $\pm$  SEM of levels derived from at least three independent experiments ( $n = 4-5$ ). \* $p < 0.05$ ; \*\* $p < 0.01$ ; and \*\*\* $p < 0.001$  comparing CX<sub>3</sub>CR1<sup>-/-</sup> mice and CX<sub>3</sub>CR1<sup>-/-</sup> recipients of CD11c<sup>+</sup> DC at indicated dpi.



responses in dLNs. Injection of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs into footpads of CX<sub>3</sub>CR1<sup>-/-</sup> mice resulted in complete activation of NK cells and CD4<sup>+</sup> T-cell responses in dLNs whereas injection of CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs resulted in impaired and weak NK cell activation and CD4<sup>+</sup> T cells. Finally, the adoptive transfer of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs was found to fully restore the resistance of CX<sub>3</sub>CR1<sup>-/-</sup> mice to JE. Adoptive transfer of CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs attenuated JE progression following peripheral JEV inoculation. Collectively, our results indicate that CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs play an important role in generating rapid and effective NK cell activation and Ag-specific CD4<sup>+</sup> T-cell responses after viral inoculation at peripheral sites, thereby inducing resistance to viral diseases.

DCs are key players in the initiation and generation of Ag-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses. They also mediate the activation of NK cells via DC-NK crosstalk (16, 17, 66). CX<sub>3</sub>CR1 is expressed on various leukocyte subsets, including monocytes, DCs, macrophages, microglia, and specific memory T cells (30–35, 68). Indeed, our results revealed that CX<sub>3</sub>CR1 was strongly expressed on CD11b<sup>+</sup> and CD11c<sup>+</sup> leukocytes, especially CD11b<sup>+</sup>CD11c<sup>+</sup> DC population, compared to CD4<sup>+</sup>, CD8<sup>+</sup> T, and NK cells. CD11b<sup>+</sup>F4/80<sup>+</sup> macrophages and CD11c<sup>+</sup> DCs exhibit different migratory properties. CD11c<sup>+</sup> DCs migrate from peripheral tissues to dLNs to interact with

T cells and induce immune responses whereas macrophages largely remain in tissues (69). We analyzed the antiviral immune responses of NK cell activation and JEV-specific CD4<sup>+</sup>/CD8<sup>+</sup> T cells in dLNs following peripheral inoculation of JEV. CX<sub>3</sub>CR1 ablation reduced NK cell activation and T-cell responses specific for JEV Ag in the dLNs, which was closely associated with delayed viral clearance in lymphoid tissues (LNs and spleen). Although CX<sub>3</sub>CR1<sup>+/+</sup> mice showed higher viral burdens temporally in lymphoid tissues at the early stage (1–3 dpi), JEV was rapidly cleared in the peripheral tissues. This viral clearance in the peripheral lymphoid tissues of CX<sub>3</sub>CR1<sup>+/+</sup> mice appeared to be mediated by rapid and effective NK cell activation and JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell response. The rapid delivery of viral Ag to cognate T cells might induce the prompt proliferation of viral Ag-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in dLNs (17, 66, 69). IFN- $\gamma$  produced from CD4<sup>+</sup> and CD8<sup>+</sup> T cells is considered to play a role in recovery from primary infection with JEV (70). NK cells might involve in regulating JE progression through reducing viral burden via IFN- $\gamma$  production and their cytolytic action, because early activation of NK cells has been associated with mild clinical diseases following viral infection (71). Also, CX<sub>3</sub>CR1-dependent recruitment of mature NK cells into the CNS may play a certain role in controlling neuroinflammation (72, 73), even though the contribution of NK cells in the CNS

was not addressed in the present study. Because JEV is already replicating at a high level by 3 dpi in CX<sub>3</sub>CR1<sup>-/-</sup> mice, NK cell activation is more plausible in the early control of viral replication at the peripheral sites than T-cell responses, which take time to develop. The early appearance of antiviral CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in CX<sub>3</sub>CR1<sup>+/+</sup> mice is likely to effectively prevent virus from invading in the CNS at the later stage (4–7 dpi) during JE progression.

To assess the cell type involved in rapid NK cell activation and JEV-specific T-cell response in dLNs of CX<sub>3</sub>CR1-competent mice, the expression of CX<sub>3</sub>CR1 on various leukocytes in both dLNs and inoculation site was analyzed. The results showed that ~90% of CD11b<sup>+</sup>CD11c<sup>+</sup> DC populations at the inoculation site (footpad) were CX<sub>3</sub>CR1-positive. The CX<sub>3</sub>CR1<sup>+</sup>CD11b<sup>+</sup>CD11c<sup>+</sup> DC population was rapidly recruited to dLNs following peripheral JEV inoculation, because the proportion of CX<sub>3</sub>CR1<sup>+</sup> cells in CD11b<sup>+</sup>CD11c<sup>+</sup> DC population was increased from 40% to around 70–80%. CX<sub>3</sub>CR1 ablation also interfered with the migration of CD11c<sup>+</sup> DCs and CD11b<sup>+</sup> myeloid cells into dLNs (popliteal LNs). The impaired migration of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs from the inoculation site to dLNs in CX<sub>3</sub>CR1<sup>-/-</sup> mice was likely to induce delayed and diminished responses of JEV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. The CX<sub>3</sub>CR1<sup>-/-</sup> mice also showed a weak activation of NK cells without changes in the absolute number of CD3<sup>-</sup>NK1.1<sup>+</sup>DX5<sup>+</sup> NK cells in dLNs. This finding was corroborated by IFN- $\gamma$  and granzyme B-producing NK cells. It is plausible that the impaired migration of CD11c<sup>+</sup> DCs affected the activation of NK cells in dLNs because DCs play a crucial role in activating NK cells via DC-NK crosstalk (66). DCs located in various tissues manifest diverse phenotypes and functional expression depending on the context of tissues. Conventional CD11c<sup>+</sup> DCs (cDC) originating in common DC precursors (CDPs) via cDC-restricted progenitors (pre-cDCs) have been detected in lymphoid and non-lymphoid tissues. They are strategically located in areas to actively detect signs of pathogens and damage in the cellular and physiological environment (74). Until now, the two main subtypes of developmentally distinct cDCs include cDC1 and cDC2, with distinct tissue-specific expression of CX<sub>3</sub>CR1 (74). For example, the cDC1 and cDC2 subtypes in the spleen express CX<sub>3</sub>CR1 with subtle differences, depending on cDC subtypes and their developmental transcription factors (74). CX<sub>3</sub>CR1<sup>+</sup>CD11b<sup>+</sup> DCs stimulate the protective effector T-cell response in the intestine whereas CD103<sup>+</sup>CX<sub>3</sub>CR1<sup>-</sup> DCs mediate Treg responses to ingested Ags and commensal organisms (75). Similarly, in the present study, migratory CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs appear to mediate the generation of effector CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses, to prevent CNS dissemination of JEV by reducing the viral burden at the peripheral sites. Furthermore, IL-12 production mediated by CX<sub>3</sub>CR1<sup>+</sup> cDC1 in the spleen is necessary to induce IFN- $\gamma$  synthesis by NK cells and CD4<sup>+</sup> Th1 differentiation (76–78). These studies reinforce our findings suggesting that CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs enhanced NK cell activation and Ag-specific CD4<sup>+</sup> Th1 and CD8<sup>+</sup> T cells in dLNs after injection into footpad. Using biallelic functional expression system of CX<sub>3</sub>CR1 (footpad injection of CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup>

DCs) and transgenic OT-II CD4<sup>+</sup> T cells, we analyzed the role of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs in generating rapid and effective NK cell activation and Ag-specific CD4<sup>+</sup> Th1 responses. CX<sub>3</sub>CR1-CX<sub>3</sub>CL1 axis not only mediates the migration of leukocytes to promote cell-to-cell interaction with an inflamed endothelium, but also regulates the development of monocytes and their survival (79). We did not investigate whether the survival of CD11c<sup>+</sup> DCs was dependent on CX<sub>3</sub>CR1 following JEV infection. CD11c<sup>+</sup> DCs are permissible for replication of JEV RNA but not productive for their progeny virus (80). While the migration of JEV Ag-bearing CX<sub>3</sub>CR1<sup>+</sup> DCs could drive increased viral titers in dLNs, the differences of CX<sub>3</sub>CR1-competent and incompetent DCs in the capture of viral Ag might be potential reason for inducing reduced JEV-specific T-cell responses in dLNs, thereby resulting in exacerbated outcomes of diseases (81, 82). However, the present study suggest that CX<sub>3</sub>CR1 is unlikely to mediate JEV replication and viral Ag capture in CD11c<sup>+</sup> DCs because CX<sub>3</sub>CR1<sup>+/gfp</sup> and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs carry comparable levels of JEV Ag (NS1 and E protein) in dLNs. Also, CX<sub>3</sub>CR1<sup>+/gfp</sup>, and CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs show comparable expression of phenotype markers related to Ag-presentation CD80, CD86, MHC I, and MHC II), indicating that both CX<sub>3</sub>CR1-competent and incompetent DCs have the same ability to present Ags. Therefore, CX<sub>3</sub>CR1 expression on CD11c<sup>+</sup> DCs appeared to involve in their migration from inoculation site to dLNs, which subsequently generated effective NK cell activation and Ag-specific T-cell responses. CX<sub>3</sub>CR1<sup>+/gfp</sup>CD11c<sup>+</sup> DCs were detected at a higher frequency in the corresponding dLNs, compared to CX<sub>3</sub>CR1<sup>gfp/gfp</sup>CD11c<sup>+</sup> DCs. Enhanced migration of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs carrying JEV Ags might increase the binding frequency to cognate CD4<sup>+</sup> and CD8<sup>+</sup> T cells in dLNs, thereby inducing rapid and robust T-cell responses as well as NK cell activation. The striking evidence supporting the regulatory role of CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs in JE progression was based on the adoptive transfer of purified CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs into CX<sub>3</sub>CR1<sup>-/-</sup> recipients. CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs displayed resistance to JE with a survival rate comparable to CX<sub>3</sub>CR1<sup>+/+</sup> wild-type mice after peripheral JEV inoculation. Our data revealed that CX<sub>3</sub>CR1<sup>-/-</sup> mice injected with CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs showed rapid expression of JEV RNA in dLNs and the spleen at the early stage after JEV inoculation. Subsequently, these viruses were rapidly cleared from the peripheral lymphoid tissues as shown in CX<sub>3</sub>CR1<sup>+/+</sup> wild-type mice. This finding strongly suggests that CX<sub>3</sub>CR1<sup>+</sup>CD11c<sup>+</sup> DCs provides resistance to JE via rapid and effective NK cell activation and Ag-specific CD4<sup>+</sup>/CD8<sup>+</sup> T-cell responses with rapid delivery of viral Ag in peripheral lymphoid tissues.

Because all JEV in dLNs appears not to be delivered by trafficking CX<sub>3</sub>CR1<sup>+</sup> DCs, our data may discount the role of other Ag-capturing cells in delivery of viral Ags from inoculation sites to blood and the spleen, such as sinus lining CD169<sup>+</sup> macrophages. Sinus lining CD169<sup>+</sup> macrophages are known to be responsible for the capture of pathogens and are frequently the first cell type infected in the spleen and dLNs (83). Furthermore, because viral Ags were detected in the spleen



within 1 dpi, it is assumed that there is abundant lymph-borne virus passing through dLN. Lymph-borne JEV is likely to be captured by subcapsular sinus macrophages that also express CX<sub>3</sub>CR1, thereby providing viral Ags to CD11c<sup>+</sup> DCs with cross-presentation to activate T cells. Indeed, JEV Ags were mostly detected within interfollicular and sinus adjacent area near germinal center, where DCs and sinus lining macrophages are co-located. The interaction between CD169<sup>+</sup> macrophages and CD11c<sup>+</sup> DCs is believed to play an important role in generating effective Ag-specific T-cell responses in dLNs (83). The role of CD169<sup>+</sup> sinus lining macrophages in delivery of viral Ags and subsequent generation of Ag-specific T-cell responses via cross-presentation was not addressed in this study. Sinus lining macrophages are reported to play a role in limiting the dissemination of neurotrophic viruses including WNV at the early stage but are not required for the generation of WNV-specific CD8<sup>+</sup> T-cell responses in dLNs (84). Therefore, the role of sinus lining macrophages in generating T-cell responses against neurotrophic viruses such as WNV and JEV remains defined.

CX<sub>3</sub>CR1-CX<sub>3</sub>CL1 axis plays an important role in facilitating adhesion and transmigration of Ly-6C<sup>hi</sup> monocytes as CX<sub>3</sub>CR1 is highly expressed on Ly-6C<sup>hi</sup> monocytes (79). Recently, a direct and evolutionarily conserved role has been suggested for CX<sub>3</sub>CR1-CX<sub>3</sub>CL1 interactions in monocyte survival (79). Thus, functional ablation of CX<sub>3</sub>CR1 on Ly-6C<sup>hi</sup> monocytes might affect their migration from peripheral sites into the CNS. A debatable issue in the present study was that the functional ablation of CX<sub>3</sub>CR1 expression on Ly-6C<sup>hi</sup> monocytes did not affect their migration into the CNS because CX<sub>3</sub>CR1-ablated mice contained increased number of Ly-6C<sup>hi</sup> monocytes in the brain. Chemokine responses can be redundant, although sequential responses are needed for selective and tailored environment of Ly-6C<sup>hi</sup> monocytes (85, 86). It is plausible that CCR2-CCL2 axis might compensate for the migration of Ly-6C<sup>hi</sup> monocytes into the CNS for CX<sub>3</sub>CR1 deficiency, because CCR2 mediates the recruitment of Ly-6C<sup>hi</sup> monocytes to inflamed tissues (87, 88). In fact, we detected higher levels of CCL2 expression in the CNS of CX<sub>3</sub>CR1<sup>-/-</sup> mice compared to CX<sub>3</sub>CR1<sup>+/+</sup> mice. A large load of JEV disseminated from peripheral sites to the CNS may strongly induce the expression of chemokines including CCL2 in the CNS, suggesting that the control of viral replication at peripheral site is important to suppress neuroinflammation caused by peripheral JEV inoculation.

Our findings contrast with the detrimental role of CX<sub>3</sub>CR1 in sterile inflammatory conditions such as atopic dermatitis (89), glomerulonephritis (38), and collagen-induced arthritis (43). In particular, the exclusive CX<sub>3</sub>CR1-dependent migration of kidney DCs promotes glomerulonephritis progression (38). In contrast, CX<sub>3</sub>CR1 is thought to exert a protective role in kidney fibrosis (90), steatohepatitis (91), and parasite-induced hepatic granuloma formation (92). The protective role of CX<sub>3</sub>CR1 in inflammatory diseases has been attributed to regulation of macrophage differentiation, proliferation, and intestinal homeostasis, without focusing on the role of CX<sub>3</sub>CR1 in leukocyte migration (90–92). These complex

roles of CX<sub>3</sub>CR1 in regulating inflammatory diseases are likely to depend on disease types (93). Bonduelle et al. demonstrated that CX<sub>3</sub>CR1 played an important role in providing protective immunity against pulmonary infection with vaccinia virus, but NK cell activation and Ag-specific T-cell responses through rapid CX<sub>3</sub>CR1-dependent delivery of viral Ags in dLNs were not addressed in their study (46). Our results strongly support the protective role of CX<sub>3</sub>CR1 through rapid migration of CD11c<sup>+</sup> DCs to present viral Ag in dLNs. Therefore, the role of CX<sub>3</sub>CR1 in JE progression after intranasal and intraperitoneal inoculation of JEV infection might be discounted due to the lack of dLNs or CNS in proximity to the injection site. In conclusion, because CX<sub>3</sub>CR1 deficiency promotes neuroinflammation induced by neurotrophic viruses such as JEV and WNV infection following peripheral inoculation, CX<sub>3</sub>CR1 inhibition should be carefully considered when treating sterile inflammation in diseases such as multiple sclerosis (63), atopic dermatitis (89), and glomerulonephritis (38).

## ETHICS STATEMENT

All animal experiments described in the present study were conducted at Chonbuk National University according to the guidelines set by the Institutional Animal Care and Use Committee (IACUC) of Chonbuk National University, and were pre-approved by the Ethics Committee for Animal Experiments of Chonbuk National University (approval number: 2013-0028). The animal research protocol used in this study followed the guidelines set up by the nationally recognized Korea Association for Laboratory Animal Sciences (KALAS). All experimental protocols requiring biosafety were approved by the Institutional Biosafety Committee (IBC) of Chonbuk National University.

## AUTHOR CONTRIBUTIONS

JC, JK, and SE conceived and designed this research. JC, JK, FH, EU, and SP performed animal study design, analysis, and interpretation. JC and EU performed Ag-specific T-cell responses. BK and KK provided critical discussion for histopathological investigations and key resources. JC, JK, and SE performed data interpretation and wrote the draft of the manuscript. All authors reviewed the manuscript.

## FUNDING

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by The Ministry of Education Science and The Ministry of Science and ICT (MSIT), Republic of Korea (2017R1E1A2A01077188, 2018R1A2B2001873, 2019R1A6A1A03033084, <http://www.nrf.re.kr>). This study was partially supported by research funds of Chonbuk National

University in 2016. The funder had no role in the study design, data collection, data analysis, decision to publish, or preparation of the manuscript.

## ACKNOWLEDGMENTS

We thank Dr. Yoon-Young Choi, Center for University Research Facility (CURF) at Chonbuk National University for providing technical assistance for FACS Aria cell sorter

and confocal laser scanning microscopy. We also thank Ms. Mi Young So for providing technical assistance for histopathological examinations.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.01467/full#supplementary-material>

## REFERENCES

- Misra UK, Kalita J. Overview: Japanese encephalitis. *Prog Neurobiol.* (2010) 91:108–20. doi: 10.1016/j.pneurobio.2010.01.008
- Huber K, Jansen S, Leggewie M, Badusche M, Schmidt-Chanasit J, Becker N, et al. *Aedes japonicus japonicus* (Diptera: Culicidae) from Germany have vector competence for Japan encephalitis virus but are refractory to infection with West Nile virus. *Parasitol Res.* (2014) 113:3195–9. doi: 10.1007/s00436-014-3983-9
- Ricklin ME, Garcia-Nicolas O, Brechbuhl D, Python S, Zumkehr B, Nougaiere A, et al. Vector-free transmission and persistence of Japanese encephalitis virus in pigs. *Nat Commun.* (2016) 7:10832. doi: 10.1038/ncomms10832
- Center for Disease. Dara from: Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific. *MMWR Morb Mortal Wkly Rep.* (2012) 66:579–83. doi: 10.15585/mmwr.mm6622a3
- Center for Disease. *West Nile Virus – Final Cumulative Maps & Data for 1999–2016.* Available online at: <https://www.cdc.gov/westnile/statsmaps/cumMapsData.html>. (accessed August 6, 2018).
- Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. *Bull World Health Organ.* (2011) 89:766–74, 74A–74E. doi: 10.2471/BLT.10.085233
- Wilson MR. Emerging viral infections. *Curr Opin Neurol.* (2013) 26:301–6. doi: 10.1097/WCO.0b013e328360dd2b
- Kim SB, Choi JY, Kim JH, Uyangaa E, Patil AM, Park SY, et al. Amelioration of Japanese encephalitis by blockage of 4-1BB signaling is coupled to divergent enhancement of type I/II IFN responses and Ly-6C(hi) monocyte differentiation. *J Neuroinflammation.* (2015) 12:216. doi: 10.1186/s12974-015-0438-x
- Kim SB, Choi JY, Uyangaa E, Patil AM, Hossain FM, Hur J, et al. Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses. *J Neuroinflammation.* (2016) 13:79. doi: 10.1186/s12974-016-0551-5
- Saxena V, Mathur A, Krishnani N, Dhole TN. An insufficient anti-inflammatory cytokine response in mouse brain is associated with increased tissue pathology and viral load during Japanese encephalitis virus infection. *Arch Virol.* (2008) 153:283–92. doi: 10.1007/s00705-007-1098-7
- Kimura T, Sasaki M, Okumura M, Kim E, Sawa H. Flavivirus encephalitis: pathological aspects of mouse and other animal models. *Vet Pathol.* (2010) 47:806–18. doi: 10.1177/0300985810372507
- Chen CJ, Ou YC, Lin SY, Raung SL, Liao SL, Lai CY, et al. Glial activation involvement in neuronal death by Japanese encephalitis virus infection. *J Gen Virol.* (2010) 91(Pt 4):1028–37. doi: 10.1099/vir.0.013565-0
- Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. *Glia.* (2007) 55:483–96. doi: 10.1002/glia.20474
- Ghosh D, Basu A. Japanese encephalitis—a pathological and clinical perspective. *PLoS Negl Trop Dis.* (2009) 3:e437. doi: 10.1371/journal.pntd.0000437
- Han YW, Choi JY, Uyangaa E, Kim SB, Kim JH, Kim BS, et al. Distinct dictation of Japanese encephalitis virus-induced neuroinflammation and lethality via triggering TLR3 and TLR4 signal pathways. *PLoS Pathog.* (2014) 10:e1004319. doi: 10.1371/journal.ppat.1004319
- Christensen JE, Thomsen AR. Co-ordinating innate and adaptive immunity to viral infection: mobility is the key. *APMIS.* (2009) 117:338–55. doi: 10.1111/j.1600-0463.2009.02451.x
- Cerboni S, Gentili M, Manel N. Diversity of pathogen sensors in dendritic cells. *Adv Immunol.* (2013) 120:211–37. doi: 10.1016/B978-0-12-417028-5.00008-9
- Gonzalez-Motos V, Kropp KA, Viejo-Borbolla A. Chemokine binding proteins: an immunomodulatory strategy going viral. *Cytokine Growth Factor Rev.* (2016) 30:71–80. doi: 10.1016/j.cytogfr.2016.02.007
- Tournadre A, Miossec P. Chemokines and dendritic cells in inflammatory myopathies. *Ann Rheum Dis.* (2009) 68:300–4. doi: 10.1136/ard.2008.095984
- Boomker JM, de Leij LF, The TH, Harmsen MC. Viral chemokine-modulatory proteins: tools and targets. *Cytokine Growth Factor Rev.* (2005) 16:91–103. doi: 10.1016/j.cytogfr.2004.12.002
- Yano R, Yamamura M, Sunahori K, Takasugi K, Yamana J, Kawashima M, et al. Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients. *Acta Med Okayama.* (2007) 61:89–98. doi: 10.18926/AMO/32882
- Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. *J Immunol.* (2000) 164:3368–76. doi: 10.4049/jimmunol.164.6.3368
- Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells *in vivo*. *Am J Pathol.* (2001) 158:855–66. doi: 10.1016/S0002-9440(10)64034-5
- Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K, et al. Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. *Eur J Immunol.* (1999) 29:1925–32. doi: 10.1002/(SICI)1521-4141(199906)29:06<1925::AID-IMMU1925>3.0.CO;2-U
- Papadopoulos EJ, Sasseti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. *Eur J Immunol.* (1999) 29:2551–9. doi: 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T
- Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. *Proc Natl Acad Sci USA.* (1998) 95:10896–901. doi: 10.1073/pnas.95.18.10896
- Yoshikawa M, Nakajima T, Matsumoto K, Okada N, Tsukidate T, Iida M, et al. TNF-alpha and IL-4 regulate expression of fractalkine (CX3CL1) as a membrane-anchored proadhesive protein and soluble chemotactic peptide on human fibroblasts. *FEBS Lett.* (2004) 561:105–10. doi: 10.1016/S0014-5793(04)00132-2
- Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. *J Atheroscler Thromb.* (2004) 11:15–21. doi: 10.5551/jat.11.15
- Wojdasiewicz P, Poniatowski LA, Kotela A, Deszczynski J, Kotela I, Szukiewicz D. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. *Arch Immunol Ther Exp.* (2014) 62:395–403. doi: 10.1007/s00005-014-0275-0
- Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1,

- which mediates both leukocyte migration and adhesion. *Cell*. (1997) 91:521–30. doi: 10.1016/S0092-8674(00)80438-9
31. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX<sub>3</sub>CR1. A chemotactic receptor for the human CX<sub>3</sub>C chemokine fractalkine and a fusion coreceptor for HIV-1. *J Biol Chem*. (1998) 273:23799–804. doi: 10.1074/jbc.273.37.23799
  32. Wolf Y, Yona S, Kim KW, Jung S. Microglia, seen from the CX<sub>3</sub>CR1 angle. *Front Cell Neurosci*. (2013) 7:26. doi: 10.3389/fncel.2013.00026
  33. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX<sub>3</sub>CR1 chemokine receptors on neurons and their role in neuronal survival. *Proc Natl Acad Sci USA*. (2000) 97:8075–8080. doi: 10.1073/pnas.090017497
  34. Dorf ME, Berman MA, Tanabe S, Heesen M, Luo Y. Astrocytes express functional chemokine receptors. *J Neuroimmunol*. (2000) 111:109–121. doi: 10.1016/S0165-5728(00)00371-4
  35. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, et al. Contribution of platelet CX<sub>3</sub>CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. *Arterioscler Thromb Vasc Biol*. (2012) 32:1186–93. doi: 10.1161/ATVBAHA.111.243485
  36. Kezic J, McMenamin PG. The monocyte chemokine receptor CX<sub>3</sub>CR1 does not play a significant role in the pathogenesis of experimental autoimmune uveoretinitis. *Invest Ophthalmol Vis Sci*. (2010) 51:5121–7. doi: 10.1167/iovs.10-5325
  37. Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, et al. CX<sub>3</sub>CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX<sub>3</sub>CR1 in their response to inflammation. *J Exp Med*. (2009) 206:595–606. doi: 10.1084/jem.20081385
  38. Hochheiser K, Heuser C, Krause TA, Teteris S, Ilias A, Weisheit C, et al. Exclusive CX<sub>3</sub>CR1 dependence of kidney DCs impacts glomerulonephritis progression. *J Clin Invest*. (2013) 123:4242–54. doi: 10.1172/JCI70143
  39. Medina-Contreras O, Geem D, Laur O, Williams IR, Lira SA, Nusrat A, et al. CX<sub>3</sub>CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. *J Clin Invest*. (2011) 121:4787–95. doi: 10.1172/JCI59150
  40. Farache J, Zigmund E, Shakhar G, Jung S. Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. *Immunol Cell Biol*. (2013) 91:232–9. doi: 10.1038/icb.2012.79
  41. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. *Cardiovasc Res*. (2011) 92:385–93. doi: 10.1093/cvr/cvr221
  42. Barlic J, Zhang Y, Murphy PM. Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX<sub>3</sub>CL1 on smooth muscle cells in a TNFalpha-NFkappaB-dependent manner. *J Biol Chem*. (2007) 282:19167–76. doi: 10.1074/jbc.M701642200
  43. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. *J Immunol*. (2004) 173:7010–6. doi: 10.4049/jimmunol.173.11.7010
  44. Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, et al. Pharmacological inhibition of the chemokine receptor, CX<sub>3</sub>CR1, reduces atherosclerosis in mice. *Arterioscler Thromb Vasc Biol*. (2013) 33:2297–305. doi: 10.1161/ATVBAHA.112.300930
  45. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX<sub>3</sub>CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. *Hepatology*. (2010) 52:1769–82. doi: 10.1002/hep.23894
  46. Bonduelle O, Duffy D, Verrier B, Combadiere C, Combadiere B. Cutting edge: Protective effect of CX<sub>3</sub>CR1+ dendritic cells in a vaccinia virus pulmonary infection model. *J Immunol*. (2012) 188:952–6. doi: 10.4049/jimmunol.1004164
  47. Choi JY, Kim JH, Patil AM, Kim SB, Uyangaa E, Hossain FMA, et al. Exacerbation of Japanese encephalitis by CD11c(hi) Dendritic cell ablation is associated with an imbalance in regulatory Foxp3(+) and IL-17(+)CD4(+) Th17 Cells and in Ly-6C(hi) and Ly-6C(lo) monocytes. *Immune Netw*. (2017) 17:192–200. doi: 10.4110/in.2017.17.3.192
  48. Lee YH, Im SA, Kim JW, Lee CK. Vanilloid receptor 1 agonists, capsaicin and resiniferatoxin, enhance MHC class I-restricted viral antigen presentation in virus-infected dendritic cells. *Immune Netw*. (2016) 16:233–41. doi: 10.4110/in.2016.16.4.233
  49. Cain MD, Salimi H, Gong Y, Yang L, Hamilton SL, Heffernan JR, et al. Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection. *J Neuroimmunol*. (2017) 308:118–30. doi: 10.1016/j.jneuroim.2017.04.008
  50. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX<sub>3</sub>CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol*. (2000) 20:4106–14. doi: 10.1128/MCB.20.11.4106-4114.2000
  51. Lannes N, Summerfield A, Filgueira L. Regulation of inflammation in Japanese encephalitis. *J Neuroinflammation*. (2017) 14:158. doi: 10.1186/s12974-017-0931-5
  52. Zigmund E, Varol C, Farache J, Elmaliha E, Satpathy AT, Friedlander G, et al. Ly6Chi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. *Immunity*. (2012) 37:1076–90. doi: 10.1016/j.immuni.2012.08.026
  53. Howe CL, LaFrance-Corey RG, Goddery EN, Johnson RK, Mirchia K. Neuronal CCL2 expression drives inflammatory monocyte infiltration into the brain during acute virus infection. *J Neuroinflammation*. (2017) 14:238. doi: 10.1186/s12974-017-1015-2
  54. Terry RL, Getts DR, Deffrasnes C, van Vreden C, Campbell IL, King NJ. Inflammatory monocytes and the pathogenesis of viral encephalitis. *J Neuroinflammation*. (2012) 9:270. doi: 10.1186/1742-2094-9-270
  55. Getts DR, Terry RL, Getts MT, Muller M, Rana S, Shrestha B, et al. Ly6c+ “inflammatory monocytes” are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. *J Exp Med*. (2008) 205:2319–37. doi: 10.1084/jem.20080421
  56. O’Koren EG, Mathew R, Saban DR. Fate mapping reveals that microglia and recruited monocyte-derived macrophages are definitively distinguishable by phenotype in the retina. *Sci Rep*. (2016) 6:20636. doi: 10.1038/srep20636
  57. Bennett ML, Bennett FC, Liddel SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci USA*. (2016) 16:E1738–46. doi: 10.1073/pnas.1525528113
  58. Lannes N, Neuhaus V, Scolari B, Kharoubi-Hess S, Walch M, Summerfield A, et al. Interactions of human microglia cells with Japanese encephalitis virus. *Virology*. (2017) 14:8. doi: 10.1186/s12985-016-0675-3
  59. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. *J Invest Dermatol*. (2000) 114:560–8. doi: 10.1046/j.1523-1747.2000.00904.x
  60. Byrne SN, Halliday GM, Johnston LJ, King NJ. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. *J Invest Dermatol*. (2001) 117:702–9. doi: 10.1046/j.0022-202x.2001.01454.x
  61. King NJ, Shrestha B, Kesson AM. Immune modulation by flaviviruses. *Adv Virus Res*. (2003) 60:121–55. doi: 10.1016/S0065-3527(03)60004-7
  62. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. *Annu Rev Immunol*. (2008) 26:293–316. doi: 10.1146/annurev.immunol.26.021607.090254
  63. Ridderstad Wolberg A, Ericsson-Dahlstrand A, Jureus A, Ekerot P, Simon S, Nilsson M, et al. Pharmacological inhibition of the chemokine receptor CX<sub>3</sub>CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. *Proc Natl Acad Sci USA*. (2014) 111:5409–14. doi: 10.1073/pnas.1316510111
  64. Hey YY, Tan JK, O’Neill HC. Redefining Myeloid Cell Subsets in Murine Spleen. *Front Immunol*. (2015) 6:652. doi: 10.3389/fimmu.2015.00652
  65. Hey YY, Quah B, O’Neill HC. Antigen presenting capacity of murine splenic myeloid cells. *BMC Immunol*. (2017) 18:4. doi: 10.1186/s12865-016-0186-4
  66. Thomas R, Yang X. NK-DC Crosstalk in Immunity to Microbial Infection. *J Immunol Res*. (2016) 2016:6374379. doi: 10.1155/2016/6374379
  67. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. *J Clin Invest*. (1997) 100:3173–83. doi: 10.1172/JCI119873
  68. Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, et al. The chemokine receptor CX<sub>3</sub>CR1 defines three antigen-experienced CD8T cell subsets with distinct roles in immune surveillance and homeostasis. *Immunity*. (2016) 45:1270–84. doi: 10.1016/j.immuni.2016.10.018



69. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. *Nat Rev Immunol.* (2005) 5:617–28. doi: 10.1038/nri1670
70. Larena M, Regner M, Lobigs M. Cytolytic effector pathways and IFN- $\gamma$  help protect against Japanese encephalitis. *Eur J Immunol.* (2013) 43:1789–98. doi: 10.1002/eji.201243152
71. Lam VC, Lanier LL. NK cells in host responses to viral infections. *Curr Opin Immunol.* (2017) 44: 43–51. doi: 10.1016/j.coi.2016.11.003
72. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, et al. The neuronal chemokine CX<sub>3</sub>CR1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. *FASEB J.* (2006) 20:896–905. doi: 10.1096/fj.05-5465com
73. Hertwig L, Hamann I, Romero-Suarez S, Millward JM, Pietrek R, Chanvillard C, et al. CX<sub>3</sub>CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. *Eur J Immunol.* (2016) 46:1984–96. doi: 10.1002/eji.201546194
74. Pakalniskyte D, Schraml BU. Tissue-specific diversity and functions of conventional dendritic cells. *Adv Immunol.* (2017) 134:89–135. doi: 10.1016/bs.ai.2017.01.003
75. Mann ER, Li X. Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells. *World J Gastroenterol.* (2014) 20:9653–64. doi: 10.3748/wjg.v20.i29.9653
76. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. *J Immunol.* (2003) 171:2366–73. doi: 10.4049/jimmunol.171.5.2366
77. Mashayekhi M, Sandau MM, Dunay IR, Frickel EM, Khan A, Goldszmid RS, et al. CD8 $\alpha$ (+) dendritic cells are the critical source of interleukin-12 that controls acute infection by *Toxoplasma gondii* tachyzoites. *Immunity.* (2011) 35:249–59. doi: 10.1016/j.immuni.2011.08.008
78. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrero M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. *Cell.* (2018) 172:1022–37.e14. doi: 10.1016/j.cell.2018.01.004
79. Panek CA, Ramos MV, Mejias MP, Abrey-Recalde MJ, Fernandez-Brando RJ, Gori MS, et al. Differential expression of the fractalkine chemokine receptor (CX<sub>3</sub>CR1) in human monocytes during differentiation. *Cell Mol Immunol.* (2015) 12:669–80. doi: 10.1038/cmi.2014.116
80. Aleyas AG, George JA, Han YW, Rahman MM, Kim SJ, Han SB, et al. Functional modulation of dendritic cells and macrophages by Japanese encephalitis virus through MyD88 adaptor molecule-dependent and -independent pathways. *J Immunol.* (2009) 183:2462–74. doi: 10.4049/jimmunol.0801952
81. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. *Nature.* (2007) 450: 110–14. doi: 10.1038/nature06287
82. Iannacone M, Moseman EA, Tonti E, Bosurgi L, Junt T, Henrickson SE, et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. *Nature.* (2010) 165:1079–83. doi: 10.1038/nature09118
83. Grabowska J, Lopez-Venegas MA, Affandi AJ, den Haan JMM. CD169<sup>+</sup> macrophages capture and dendritic cells instruct: the interplay of the gatekeeper and the general of the immune system. *Frontiers Immunol.* (2018) 9:2472. doi: 10.3389/fimmu.2018.02472
84. Winkelmann ER, Widman DG, Xia J, Johnson AJ, van Rooijen N, Mason PW, et al. Subcapsular sinus macrophages limit dissemination of West Nile virus particles after inoculation but are not essential for the development of West Nile virus-specific T cell responses. *Virology.* (2014) 450–1:278–89. doi: 10.1016/j.virol.2013.12.021
85. Meloni F, Solari N, Miserere S, Morosini M, Cascina A, Klersy C, et al. Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-beta, MIP3-alpha, MDC and their specific receptors. *Transpl Immunol.* (2008) 18:275–80. doi: 10.1016/j.trim.2007.08.004
86. Colobran R, Pujol-Borrell R, Armengol MP, Juan M. The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. *Clin Exp Immunol.* (2007) 148:208–17. doi: 10.1111/j.1365-2249.2007.03344.x
87. Iijima N, Mattei LM, Iwasaki A. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. *Proc Natl Acad Sci USA.* (2011) 108:284–9. doi: 10.1073/pnas.1005201108
88. Uyangaa E, Kim JH, Patil AM, Choi JY, Kim SB, Eo SK. Distinct upstream role of type I IFN signaling in hematopoietic stem cell-derived and epithelial resident cells for concerted recruitment of Ly-6Chi monocytes and NK cells via CCL2-CCL3 cascade. *PLoS Pathog.* (2015) 11:e1005256. doi: 10.1371/journal.ppat.1005256
89. Staumont-Salle D, Fleury S, Lazzari A, Molendi-Coste O, Hornez N, Lavogiez C, et al. CX<sub>3</sub>CL1 (fractalkine) and its receptor CX<sub>3</sub>CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. *J Exp Med.* (2014) 211:1185–96. doi: 10.1084/jem.20121350
90. Engel DR, Krause TA, Snelgrove SL, Thiebes S, Hickey MJ, Boor P, et al. CX<sub>3</sub>CR1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages. *J Immunol.* (2015) 194:1628–38. doi: 10.4049/jimmunol.1402149
91. Schneider KM, Bieghs V, Heymann F, Hu W, Dreytmueller D, Liao L, et al. CX<sub>3</sub>CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. *Hepatology.* (2015) 62:1405–16. doi: 10.1002/hep.27982
92. Ran L, Yu Q, Zhang S, Xiong F, Cheng J, Yang P, et al. Cx3cr1 deficiency in mice attenuates hepatic granuloma formation during acute schistosomiasis by enhancing the M2-type polarization of macrophages. *Dis Model Mech.* (2015) 8:691–700. doi: 10.1242/dmm.018242
93. Lee M, Lee Y, Song J, Lee J, Chang SY. Tissue-specific role of CX<sub>3</sub>CR1 expressing immune cells and their relationships with human disease. *Immune Netw.* (2018) 18:e5. doi: 10.4110/in.2018.18.e5

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Choi, Kim, Hossain, Uyangaa, Park, Kim, Kim and Eo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.